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Summary 
Alzheimer’s disease (AD) is a chronic neurodegenerative disease of the central 
nervous system (CNS) characterized by progressive cognitive decline. AD is 
the most common cause of all dementia cases worldwide, and as a result of 
demographic aging the number of affected individuals grows at an alarming 
rate. The amyloid hypothesis of Alzheimer’s disease (AD) emphasizes amyloid-
β peptide (Aβ) as primary cause of the disease, with toxic effects on synapses 
leading to cognitive decline and memory impairments. Beta site amyloid 
precursor protein cleaving enzyme 1 (BACE1) as the rate-limiting enzyme of 
amyloidogenic processing of amyloid precursor protein (APP), is one of the 
prime drug targets for the treatment of AD. However, despite the development 
of potent and selective small-molecule BACE1 inhibitors, so far all human 
clinical trials have failed to rescue the cognitive decline in AD patients. Recent 
findings indicate that treatment has to be commenced before AD symptoms 
arise, since in symptomatic patients β-amyloid deposition has already reached 
a plateau. Moreover, several studies have described dose-dependent adverse 
effects in animal models. Therefore, it is a central requirement to develop a 
treatment strategy that is therapeutically effective and at the same time avoids 
excessive interference with physiological function of BACE1. 
In this study, transgenic AD mice were treated at an early stage of β-amyloid 
pathology with the potent, blood brain barrier penetrating BACE1 inhibitor NB-
360. Longitudinal in vivo two-photon imaging was performed to repeatedly 
monitor individual amyloid plaques, presynaptic boutons and axonal 
dystrophies in living mice. In APPPS1 mice pharmacological BACE1 inhibition 
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fails to revert but significantly reduces the progressive amyloid deposition and 
mitigates presynaptic pathology. Notably, the data show that plaque seed 
formation, rather than the subsequent phase of gradual plaque growth, is most 
sensitive to BACE1 inhibition. These results imply, that preventive BACE1 
inhibitor treatment is required to achieve therapeutic efficacy. For clinical 
therapy, to exploit the particular susceptibility of plaque formation to BACE1 
inhibition, a dosage has to be empirically determined that effectively halts 
formation of new plaques rather than aiming at halting plaque growth. This 
strategy might optimally balance potential mechanism-based adverse effects 
and efficacious reduction of β-amyloid deposition. 
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Zusammenfassung 
Morbus Alzheimer ist eine chronische neurodegenerative Erkrankung des 
zentralen Nervensystems und äußert sich in progressivem Verlust kognitiver 
Funktionen und Gedächtnisleistung. Die Erkrankung ist die weltweit häufigste 
Ursache für Demenz und aufgrund demografischer Alterung in den Industrie-
ländern, nimmt die Zahl der Alzheimer Patienten stetig zu. Der Amyloid-
Kaskaden-Hypothese zufolge, wird die Alzheimer Erkrankung durch 
pathologische Akkumulation und Aggregation des Aβ-Peptids (Aβ) ausgelöst. 
Aβ wird durch sequentielle enzymatische Spaltung des Amyloid-Vorläufer-
proteins APP produziert. Die β-Sekretase BACE1 initiiert den ersten Schritt 
dieses sogenannten amyloiden Prozessierungswegs und ist somit eines der 
aussichtsreichsten Wirkstoffziele zur Senkung des Aβ-Spiegels. Im Verlauf der 
letzten Jahre wurden sehr wirksame und zugleich selektive BACE1 Inhibitoren 
hergestellt, doch bislang sind klinische Studien daran gescheitert, den 
progressiven Gedächtnisverlust aufzuhalten. Neueste Erkenntnisse weisen 
darauf hin, dass die Behandlung bereits vor dem Auftreten der ersten 
Symptome begonnen werden muss, da in symptomatischen Patienten die 
Ablagerung von Aβ in den meisten Fällen bereits abgeschlossen ist. Hinzu 
kommt, dass in den letzten Jahren vermehrt negative Begleiterscheinungen der 
Behandlung mit BACE1 Inhibitoren in Mäusen bekannt geworden sind. Die 
entscheidende Herausforderung ist somit, eine Behandlungsstrategie zu 
entwickeln, welche einerseits die physiologische Funktion von BACE1 nicht zu 
stark beeinträchtigt, aber zugleich therapeutische Effizienz gewährleistet. 
In der vorliegenden Studie wurden transgene Alzheimer Mäuse in einem frühen 
Stadium der β-amyloiden Pathologie mit dem potenten BACE1 Inhibitor NB-
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360 behandelt. Mittels chronischer in vivo Mikroskopie konnten einzelne 
β-amyloide Plaques, präsynaptische Boutons und axonale Dystrophien in 
lebenden Mäusen verfolgt werden. Die Behandlung erbrachte zwar keinen 
Rückgang der Aβ Ablagerung, konnte jedoch deren Fortschreiten verringern, 
sowie die progressive axonale Pathologie abschwächen. Insbesondere zeigten 
unsere Daten, dass die BACE1 Inhibitor Behandlung einen wesentlich 
größeren Einfluss auf die Bildung neuer β-amyloider Plaques, als auf deren 
Wachstum hatte. Diese Ergebnisse weisen darauf hin, dass die Behandlung 
mit BACE1 Inhibitoren präventiv erfolgen muss. Für die klinische Anwendung 
könnte man sich die besondere Anfälligkeit der Neubildung von Plaques zu 
Nutze machen und über empirische Versuche einen Dosisbereich bestimmen, 
welcher ausreicht, die Neubildung von Plaques zu unterdrücken. Diese 
Strategie könnte zu einer ausgewogenen Behandlung führen, welche die 
progressive Aβ Ablagerung verzögert und gleichermaßen das Auftreten von 
Nebenwirkungen verhindert. 
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1. Introduction 
1.1 Alzheimer’s disease 
Alzheimer’s disease (AD) is a chronic neurodegenerative disease of the central 
nervous system (CNS) characterized by progressive cognitive decline (1). AD 
is the most common cause of all dementia cases (2) and the fourth leading 
cause of death after cardiovascular diseases, cancer and stroke. Currently, 
about 36 million people are affected worldwide, and as a result of demographic 
aging the number of affected individuals grows at an alarming rate (3,4). Due to 
the immense economical and emotional burden for patients, their family and 
the whole society, it will be one of the main challenges of this century to 
develop a therapy for AD. To date, more than 100 years after the first 
description of AD by Alois Alzheimer (5) no medication has proven to delay or 
halt the progression of the disease in human patients (6). Given the current 
lack of an effective treatment there is an urgent need in developing and 
evaluating disease-modifying therapies. 
1.1.1 Clinical symptoms and disease etiology 
AD etiology can be subdivided into three stages (7): 
1. The early stage is characterized by impaired episodic memory – the 
capability to memorize autobiographical incidents. These deficits are 
probably due to progressive degeneration of the medial temporal lobe and 
the hippocampus (8). 
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2. In the advanced stage, memory function progressively declines and patients 
require support from other people. Notably, a rapid deterioration of 
episodical and semantic memory occurs. The latter includes the whole 
factual knowledge, like the meaning of words and their relationships in 
abstract form. In conjunction there is a change in the emotional state and 
personality of patients. 
3. In the final stage, the cognitive capabilities are massively affected. Patients 
lose the capability to communicate and are physically strongly restricted. In 
many cases muscles stiffen and reflexes are lost. The most common cause 
of death is pneumonia, which results from problems to regulate the larynx 
that leads to swallowing of liquids and food. 
The mean lifespan after onset of symptoms is seven years with strong inter-
individual variations (9). However, the neurodegenerative process already 
starts long before the symptomatic stage. In biomarker studies, pathological 
changes could be detected already 25 years before symptom onset in patients 
with inherited AD (1). 
1.1.2 Neuropathological characteristica 
On the macroscopic level AD is characterized by progressive cortical atrophy, 
mainly affecting medial temporal lobe and associated brain regions. This 
process can be detected quite early during clinical pathological progression by 
applying magnetic resonance imaging (MRI) and manifests as dilation of the 
lateral ventricles (10). On the microscopic level AD is characterized by the 
presence of intracellular neurofibrillary tangles composed of hyperphosphoryla-
ted tau and extracellular cerebral amyloid plaques composed of the 40 – 42 
amino acid β-amyloid peptide (11–13). These lesions are thought to be the 
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primary cause for degeneration of synapses, neuron loss (14) and inflammation 
(15–17). 
1.1.3 Amyloid plaques 
The term “amyloid” plaques was coined by the German pathologist Rudolf 
Virchow and originates from the Latin translation of starch “amylum”. In 1854, 
Virchow was the first to detect plaques, by applying a iodine staining which 
labels starch (18). Even though it was shown later that amyloid plaques are 
composed mainly of protein (19,20), the term was maintained for historical 
reason.  
Amyloid plaques arise from aggregation of β-amyloid (Aβ) that is produced 
from sequential proteolytic cleavage of the amyloid precursor protein (APP) 
(21,22). Plaques are typically of spheric morphology, with a diameter ranging 
up to 200 µm (23). Generally two types of amyloid plaques can be 
distinguished. Neuritic plaques have a compact core, composed of amyloid 
fibrils with characteristic parallel beta-pleated sheet conformation (24). 
Typically, neuritic plaques are surrounded by reactive astrocytes, activated 
microglia and dystrophic neurites (25,26). Diffuse plaques are amorphous 
structures and have no sharply defined outer boundary. These plaques lack a 
dense core, and instead, Aβ deposition is evenly distributed throughout the 
whole plaque (26). Unlike neuritic plaques, diffuse plaques are not detrimental 
to the neuropil. They are not considered as pathological criterium for diagnosis 
of AD (27), since they are frequently found in cognitively unaffected aged 
humans. 
The β-amyloid pathology typically initiates locally at specific sites and then 
gradually disperses into adjoining unaffected regions (28–33). The sequential 
order in which distinct brain regions are affected can be divided in five phases 
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(33). (1) isocortex, (2) entorhinal cortex and hippocampus, (3) striatum and 
diencephalon, (4) different nuclei of the brainstem, (5) cerebellum. While 
neuritic plaques are clearly detrimental to surrounding neuropil, clinical studies 
have shown that cognitive decline in Alzheimer patients does not correlate well 
with plaque density nor the total plaque burden (34–36). 
1.1.4 Tangles 
Neurofibrillary tangles develop due to hyperphosphorylation, misdistribution 
and ultimate intracellular aggregation of the protein tau (37,38). Native tau has 
no rigid three-dimensional structure but can adopt different conformations (39). 
Even though it is difficult to experimentally retrace the conformational changes 
of tau during the process of aggregation, there is a general consensus about 
the initiation of tau aggregation. Tau has a lysine-rich subdomain that can bind 
and thereby stabilize the negatively charged β-tubulin subunit of microtubules 
(40–44). Due to this characteristic, tau plays an important role in formation of 
cell protrusions (45), cell polarity (11,46) and regulation of axonal transport 
(47). Under pathological conditions, the tau protein is hyperphosphorylated 
(48,49) and binding to microtubules is reduced (50). As a consequence, axonal 
transport is impaired (51) and tau is aberrantly distributed into the 
somatodendritic compartment (52,53). Enrichment of tau in the cytosol causes 
a conformational change into the Alz50-conformation (a specific epitope is 
detected by antibody Alz50) that promotes aggregation of tau (54). Subsequent 
postranslational modifications cause formation of paired helical filaments with 
β-sheet structure similar to amyloid fibrils (55). These intraneuronal aggregates 
are designated neurofibrillary tangles and even remain as extracellular deposits 
after the neuron has perished (52,56). Hyperphosphorylated tau aggregates 
also develop in dystrophic neurites in proximity to neuritic plaques and are 
called neuropil threads (57). Similar to sequential spreading of amyloid 
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pathology, tau pathology also proceeds in temporally and spatially defined 
manner. The german neuropathologist Heiko Braak divided the progression of 
tau pathology in six stages (58): (stage l and ll) trans-entorhinal and entorhinal 
cortex, (stage lll and lV) hippocampus, (stage V and Vl) isocortex. Since tau 
pathology more reliably correlates with cognitive decline than amyloid 
pathology (59), this classification by Braak is used as standard for clinical post 
mortem diagnosis for AD (58). 
1.1.5 Synaptic failure 
AD is characterized by progressive degeneration of synapses and neurons 
which manifests post mortem as strong atrophy of the brain (60,61). The most 
severely affected brain regions are the hippocampus and anatomically 
adjoining entorhinal, parietal and frontal cortex (62–64). Loss of presynaptic 
boutons was revealed by immunohistochemical studies in which a reduction of 
the presynaptic marker synaptophysin could be detected (65) and is most 
pronounced in close proximity to amyloid plaque deposits (66–74). In the AD 
brain, plaques are typically surrounded by swollen, dystrophic neurites (Figure 
1) (25,75) and the majority of these peri-plaque dystrophies is presynaptic or 
axonal in origin (76–81). However, while dendrites rarely form dystrophies, 
dendritic spines are particularly reduced around plaques (82). Numerous 
studies have shown that synapses are a structural correlate for learning and 
memory (83–85). Indeed, the progressive cognitive decline correlates better 
with synapse loss than any other neuropathological phenotypes (86–88). 
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Figure 1. Aβ plaques are surrounded 
by axonal dystrophies. Microscopic 
image of a neuritic plaque from a 7 
months old APPPS1xVGLUT1
Venus
 
mouse (89,90). β-amyloid fibrils were 
stained with the dye Methoxy-X04 (cyan) 
and VGLUT1-positive boutons and 
axonal dystrophies are labelled due to 
endogenous expression of VGLUT1
Venus
 
(green). Scale bar represents 10 μm. 
 
1.1.6 Molecular biology 
Due to methodological progress in molecular biology and genetics, knowledge 
on the pathological mechanisms underlying AD could be greatly expanded in 
the last three decades. In 1984, for the first time, the biochemists George 
Glenner and Philip Wong purified and sequenced the main constituent of 
amyloid plaques – the Aβ peptide (91). Only three years later, APP was 
identified as the precursor protein for Aβ generation (92). In the majority of 
patients, AD occurs idiopathically without identifiable cause, and only 
approximately 5% of cases suffer from inherited autosomal dominant type (93). 
Genetic studies have shown that some patients suffering from inherited AD 
have point mutations in the APP gene (94,95), which facilitate generation and 
aggregation of Aβ and thereby the formation of Aβ plaques (96,97). These 
observations lead to the ’Amyloid cascade hypothesis’, which states that 
excessive generation and subsequent deposition of Aβ in the brain is the 
causal initiator of a cascade of pathological events that ultimately lead to AD 
(98). 
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1.1.7 Proteolytic processing of APP 
APP is a ubiquitously expressed transmembrane glycoprotein of type 1 (95). In 
mammals, APP together with homologous amyloid precursor like proteins 1 
and 2 (APLP1 and APLP2) constitute the APP-protein family. However, only 
APP contains the Aβ domain necessary for Aβ plaque formation (99–101). In 
humans, the APP gene is localized on chromosome 21 (92,102–104) and is 
present in three different splice variants of 695, 751 or 770 amino acids. While 
APP751 and APP770 are expressed in almost all tissues, the variant APP695 
is primarily expressed by neurons and localizes to synapses, dendrites and 
axons (105–109). After initial translation, APP traffics along the secretory 
pathway and matures by posttranslational modifications, including 
glycosylation, phosphorylation and sulfation (110). Subsequently, the APP 
holoprotein is proteolytically cleaved either along the amyloidogenic pathway or 
the non-amyloidogenic pathway (111). 
In the non-amyloidogenic pathway, APP is initially cleaved by the 
metalloprotease ADAM10 (a disintegrin and metalloproteinase 10) within the 
Aβ domain between amino acids 16 and 17 (112). This cleavage generates the 
soluble ectodomain sAPPα (113,114) and the membrane bound carboxy-
terminal fragment, αCTF (C83). αCTF is further processed by γ-secretase, 
(115) yielding the amyloid precursor protein intracellular domain (AICD) and a 
series of short hydrophobic peptides including Aβ17–40 and Aβ17–42, which 
are collectively called p3 fragments (116). Outside the CNS, APP is 
preferentially cleaved by α-secretase (117–119). 
The amyloidogenic pathway (Figure 2), leads to the generation of Aβ and is 
initiated by proteolytic cleavage of APP by β-site APP cleaving enzyme 1 
(BACE1). BACE1 processing of APP takes place in endosomes, since their 
acidic environment offers optimal conditions for enzymatic activity of BACE1 
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with an optimal pH of approximately 5 (120,121). Proteolytic cleavage of APP 
by BACE1 is the rate-limiting step in the cascade and results in the generation 
of a large soluble extracellular fragment commonly referred to soluble APP-β 
(sAPPβ) which is released into the extracellular space and a membrane 
anchored C-terminal fragment (CTFβ or C99). CTFβ is finally cleaved by the 
γ-secretase complex. γ-secretase is a multi-subunit aspartyl protease that 
consists of nicastrin, the stabilizing factor APH-1, presinilin-enhancer 2 and the 
catalytic subunits presinilin-1 and presinilin-2 (122). γ-secretase cleaves APP- 
CTFβ and many other type l transmembrane proteins within their 
transmembrane domains (123–125). CTFβ processing results in the generation 
of the membrane-anchored nuclear-localizing fragment AICD and Aβ-peptide 
which is released into the extracellular space (110,126).  
The initial cleavage by γ-secretase takes place within the transmembrane 
domain close to the cytoplasmic border of the membrane and releases AICD. 
Subsequently, the remaining long Aβ fragment is successively cut producing 
Aβ-peptides ranging from 37 to 43 amino acids (127). Mutations in γ-secretase 
and APP destabilize the intermediary enzyme-substrate complex, leading to 
enhanced dissociation and thereby release of longer and more amyloidogenic 
peptides (128). Thus, sequential cleavage of APP by γ-secretase is a key 
determining feature that can increase an individual’s risk of developing AD. The 
different Aβ species have different conformational characteristics (129). In 
comparison to the most abundant variant Aβ40, the variant Aβ42 has a tendency 
to aggregate into amyloid fibrils (130,131). Indeed, the main constituent of 
fibrillar Aβ in neuritic plaques is Aβ42 (132). In contrast, shorter Aβ peptides 
including the predominant Aβ40 species, inhibit Aβ aggregation and deposition 
(133,134). 
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1.1.8 Amyloid cascade hypothesis 
Accumulation of Aβ in protein aggregates triggers numerous pathophysiological 
changes that ultimately lead to cognitive dysfunction (135). The amyloid 
cascade hypothesis is the prevailing theory that describes the sequence of 
pathological changes that lead to AD (98,136,137) and was postulated in 1991 
by John Hardy and Dennis Selkoe. The amyloid cascade hypothesis puts 
forward the accumulation of Aβ as initial and causative event. The aggregation 
of Aβ has detrimental effect on synapses and causes gliosis as well as 
hyperphosphorylation of tau, leading to generation of intracellular tau fibrils. 
Finally, the cascade results in progressive synaptic and neuronal degeneration 
and thereby culminates in dementia with characteristic plaque and tangle 
pathology (138). 
The observation that Aβ is the main constituent of β-amyloid plaques and 
cerebral angiopathies (91,139) does not causally link Aβ pathology to AD. 
However, genetic studies provide strong indications for a clear correlation. In 
Down syndrome patients the chromosome 21, which contains the APP gene, is 
present three times, resulting from a chromosome aberration. In these patients, 
Aβ production and thereby β-amyloid deposition are enhanced. Almost all 
cases develop clinical symptoms of AD until 55 years of age (136,140–142). Up 
to now, all mutations linked with the inherited form of AD are related to the 
cellular machinery implicated in Aβ production (143) and either occur in the 
APP-gene (95,144) or in catalytical subunits of PS1 and PS2 of the γ-secretase 
complex (145). In addition, mutations within the β-cleavage site of APP that 
reduce the production of Aβ confer protection against cognitive decline in the 
elderly (146) and knockout of the Bace1 gene abrogates amyloid pathology in 
AD mice (147). The only genetic risk factor for AD identified so far is 
Apolipoprotein E4 (ApoE4). The protein is secreted by glia and is essentially 
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involved in binding and clearance of Aβ from the CNS (148). Recently, it was 
shown that ApoE4 exacerbates neuronal Aβ production via a signal trans-
duction pathway whereby ApoE activates a non-canonical mitogen-activated 
protein (MAP) kinase cascade that enhances APP transcription and thereby Aβ 
production (149). 
The amyloid cascade hypothesis is based on the assumption that the 
occurrence of tau pathology is a consequence of β-amyloid deposition. This 
notion is supported by results from patients with frontotemporal dementia, a 
neurodegenerative disease characterized by massive tau pathology despite 
lack of β-amyloid pathology (150,151). This indicates that pathological 
accumulation of tau per se is neurotoxic but cannot initiate Aβ pathology 
(136,152). Conversely, in tau overexpressing mouse models, tau pathology is 
aggravated by coexpression of mutated human APP (153). Further evidence on 
the interplay between Aβ and tau pathology was obtained from experiments in 
transgenic mouse models and cell culture. Genetic knockout of tau ameliorates 
Aβ induced learning deficits, reduced long-term potentiation (LTP) and nerve 
cell loss (154–156). The molecular mechanisms of tau induced synaptotoxicity 
of Aβ are still under investigation. Aβ aggregation triggers hyperphosphoryla-
tion of tau via the CAMKK2-AMPK signaling cascade (calcium/calmodulin-
dependent protein kinase kinase 2, 5´ adenosine monophosphat-activated 
protein kinase) and thereby causes mislocalization of tau to the dendritic 
compartment (157). Aberrant localization of tau in dendritic spines has been 
claimed to lead via kinase Fyn to hyperphosphorylation of NMDA-receptors (N-
Methyl-D-Aspartat). Subsequently, excessive release of neurotransmitter 
glutamate results in excitotoxicity and degeneration of synaptic terminals 
(158,159). 
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Figure 2. Illustration of the amyloid cascade hypothesis. Proteolytic cleavage by BACE1 
initiates amyloidogenic processing of APP and generates CTFβ and sAPPβ which is released 
into the extracellular space. CTFβ is further processed by γ-secretase, resulting in the 
formation of Aβ and AICD. Aβ and in particular the Aβ42 variant, is prone to aggregation, which 
results in the formation of Aβ fibrils and ultimately plaques. 
1.2 BACE1 
BACE1 is an aspartate endopeptidase and catalyzes the initial and rate-limiting 
step of amyloidogenic processing of APP to form the toxic β-amyloid peptide 
(Aβ). Therefore, BACE1 is one of the primary therapeutic targets to lower the 
cerebral Aβ level in AD patients. The central role of BACE1 in processing of 
APP was discovered for the first time in 1999 by five different research groups 
simultaneously (160–164). In these studies, a second aspartate-endopeptidase 
(BACE2) was identified with 64% amino acid sequence homology. Both 
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endopeptidases can be detected in diverse tissues, but BACE1 is mainly 
produced in the brain (162,164,165). Also, BACE1 but not BACE2 is the 
relevant β-secretase in vivo for the processing of APP (166). The catalytic 
domain of BACE1 enzyme has two characteristic (DT/SGS/T) motifs similar to 
the pepsin family of aspartate proteases (167). However, in contrast to this 
family of proteases, BACE1 is a type l transmembrane protein. The C-terminus 
reaches into the cytosol and the N-terminus which contains the active center is 
located on the luminal side.  
1.2.1 Physiological function 
Within the plasma membrane, BACE1 localizes to lipid rafts (168) and specific 
lipids in these cholesterol-rich microdomains can promote activity of BACE1 
(168). Intracellularly BACE1 localizes to diverse subcellular organelles. BACE1 
is initially synthesized as an inactive pro-enzyme and is converted into the 
active form in the trans-Golgi network (169,170). The transport of BACE1 in the 
endosomal-lysosomal system or incorporation into lipid rafts is regulated 
through phosphorylation and palmitoylation (171,172). The enzyme has 
maximal catalytical activity at low pH (pH 4.5 – 6.0) in the acidic lumen of the 
trans-Golgi network and endosomes (173). Previous studies have shown that 
BACE1 and APP interact in endosomes (173) and the application of 
compounds that increase endosomal pH effectively inhibit Aβ production (174). 
Thus, the majority of APP processing takes place in endosomes. The past 
decade has revealed numerous substrates of BACE1, including 33 neuronal 
proteins. Thus, BACE1 is one of the most important sheddases in the nervous 
system (175). The substrates can be divided according to their physiological 
function into two different categories. The first group are proteins with a 
synaptic function. The other group are proteins that interact with the 
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extracellular matrix of astrocytes and oligodendrocytes and thereby regulate 
growth of axons (167). 
BACE1–/– mice are viable and fertile. However, due to the important role of 
BACE1 in synaptic function, Bace1 gene knockout leads to diverse neurological 
phenotypes, including impaired learning and memory, epileptic seizures, 
locomotor hyperactivity and schizophrenia-associated behavioral changes 
(176–178). Pharmacological inhibition of BACE1 decreases spine turnover and 
total spine density, which indicates a critical role of BACE1 in structural and 
functional synaptic plasticity in mice (179,180). 
The complex phenotypes of Bace1–/– mice are at least partly mediated by the 
BACE1 substrates Sez-6 (seizure-related gene 6) (181) and the Nav β-subunit 
(182). Sez-6 is a type 1 membrane protein that localizes to dendrites and is 
predominantly cleaved by BACE1. Sez-6 knockout mice have reduced spine 
density and impaired excitability of pyramidal neurons in cortical layer V (181). 
The structural and functional synaptic plasticity is primarily mediated via 
BACE1 mediated cleavage of Sez-6 (180). 
Epileptic seizures in Bace1–/– mice are probably a consequence of reduced 
processing of the Nav β-subunit, that controls expression and surface 
localization of sodium channels (183,184). As a result, the density of voltage 
gated sodium channels is increased in Bace1–/– mice which causes increased 
neuronal excitability and thus increased susceptibility to epileptic seizures. 
Among the BACE1 substrates that are involved in regulation of axonal growth, 
especially the cell adhesion protein CHL1 (close homolog of L1) is well 
characterized. CHL1 is a type 1 membrane protein that is sequentially cleaved 
by ADAM8 (A Disintegrin and metalloproteinase domain-containing protein 8) 
(185) and BACE1 (175). The soluble ectodomain can interact with Neurophilin-
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1 und Semaphorin 3A, and thereby influences axonal targeting (186,187). As a 
result, Chl1 knockout mice as well as Bace1–/– mice have impaired axonal 
connectivity of hippocampal mossy fibers within the infrapyramidal bundle. 
Additionally, the total length of the infrapyramidal bundle is reduced by 
approximately 30% in Bace1–/– mice (188). Since the length of the 
infrapyramidal bundle is correlated with memory performance in mice (189), 
this might at least in part account for the cognitive deficits in Bace1–/– mice. 
Also in the peripheral nervous system, numerous functions of BACE1 have 
been described. Genetic ablation of the Bace1 gene causes hypomyelination of 
nerves in mice (190). This effect is due to reduced proteolytic processing of the 
BACE1 substrate NRG1 (Neuregulin 1) isoform type lll (190), which plays an 
important role in early postnatal myelination (191). NRG1 type I is also 
processed by BACE1. Since NRG1 type l has an important function in the 
formation of muscle spindles, a reduction of NRG1 type l processing causes 
reduced formation of muscle spindles in Bace1–/– mice (192). This effect could 
be reproduced by pharmacological inhibition of BACE1 in adult wild type mice 
(192). BACE1 mediated processing of NRG1 type l is not only required for the 
formation of muscle spindles during their development but also for their 
maintenance in adulthood. Future clinical trials will reveal whether 
pharmacological BACE1 inhibition causes a similar phenotype in humans. 
1.2.2 Pathophysiology of BACE1 in AD 
In the AD brain, amyloid plaques are surrounded by swollen presynaptic 
dystrophic neurites that are enriched with BACE1 (78,81,193,194). This 
excessive accumulation of BACE1 might be the reason for the two-fold 
increased BACE1 levels in brains of AD mice and AD patients compared to 
healthy individuals (195–200). One possible mechanism for this aberrant 
localization has been brought up recently by Gowrishankar et al. (77). 
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According to the hypothesis of this work, Aβ causes microtubule disruption and 
motor protein mis-localization by an as yet undefined cascade (76,77). Since 
BACE1 degradation occurs via the lysosomal pathways (201,202) and 
therefore depends on retrograde transport to the cell body, a local disruption of 
microtubules and motor protein mis-localization would impair lysosomal 
maturation. Consequently, BACE1 and other proteins accumulate in peri-
plaque dystrophic neurites (76,77). Excessive enrichment of BACE1 in the 
proximity of plaques might cause a vicious pathogenic cycle (203). According to 
this hypothesis BACE1 increases local Aβ production at plaques and thereby 
accelerates amyloid deposition even more. 
1.3 Therapeutic approaches 
The existing AD drugs are just symptomatic therapies, such as the acetyl-
cholinesterase inhibitors and the N-methyl D-aspartate receptor antagonist 
memantine. Both cannot stop the progressive neurodegeneration but rather 
delay progression by about 3 months. Alternatively, epidemiological studies 
and experiments in transgenic mice have shown that ‘lifestyle’ interventions – 
such as a healthy diet and physical or cognitive exercise – can reduce the 
incidence of dementia and dementia-related biochemical changes in the brain 
(204,205). However, efficacy of current medication is limited to the very early 
stages of the disease and only provides symptomatic relief. 
The amyloid cascade hypothesis has led to the identification of therapeutic 
targets for treatment or prevention of AD and provides the rationale for the 
current main focus of the pharmaceutical industry to target Aβ aggregates. The 
three proteases that are involved in APP processing, namely α-secretase, 
BACE1 and γ-secretase, are of particular interest, since they can be targeted 
by small molecule compounds in vitro and in vivo. 
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Enhancing processing of APP by α-secretases is protective in the context of 
AD because the enzymes cleave within the Aβ sequence and thereby prevent 
the production of Aβ (206,207). However, ablation of many genes that code for 
α-secretase have turned out to be lethal (206–208). For example, deletion of 
ADAM10 is lethal in mid-gestation (208). So far, drugs that directly activate α-
secretase have not been developed, and thus it is unclear if this strategy is free 
of adverse side effects and if it might attenuate AD symptoms. 
γ-secretase inhibitors decrease Aβ production in human and mouse brains, and 
chronic administration decreases Aβ deposition in APP mouse models (209–
212). However, since γ-secretase cleaves numerous transmembrane proteins, 
mechanism-based adverse effects pose a major obstacle for the successful 
clinical development of these compounds. For example, γ-secretase 
processing of Notch1 is crucial for Notch signaling (213) and deletion of PS1 is 
embryonically lethal in mice (214,215). γ-secretase modulators alter the profile 
of Aβ peptides produced by γ-secretase activity in vitro and in vivo (216,217). 
Such compounds can selectively reduce the levels of Aβ42 and can be safely 
administered in the long term (218). However, so far clinical attempts failed to 
rescue the cognitive decline. 
1.3.1 Pharmacological inhibition of BACE1 
There are several indications that BACE1 inhibition therapy should be 
beneficial for the treatment of AD. Discovery of the protective APP point 
mutation Ala673Thr indicates that life-long reduction of Aβ production by 40% 
might suffice to prevent AD (219). Additionally, genetic ablation of Bace1 in 
transgenic APP overexpressing mice, blocks the production of Aβ and thereby 
β-amyloid deposition as well as plaque-associated pathology (147,220,221). 
Initial studies of Bace1–/– mice did not detect developmental or behavioral 
impairments, nor histological alterations (222), which raised the hope that 
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inhibition of BACE1 might be free of adverse effects. Over the course of several 
years various inhibitors were developed. Initial peptide inhibitors that modelled 
the active center of BACE1, effectively and specifically inhibited BACE1 activity 
in vitro. However, these compounds were too large to pass the blood brain 
barrier (223). The development of small-molecule non-peptide inhibitors solved 
this problem (224) and consequently, several BACE1 inhibitors have entered 
human clinical trials (225–228). Small-molecule BACE1 inhibitors effectively 
lower brain Aβ levels (225,229,230) and can reduce plaque burden in mice 
(231–234). However, two clinical trials have failed so far due to unspecific side 
effects (6) or lack of efficacy, as documented by the recent failure of the phase 
2/3b EPOCH trial of verubecestat (ClinicalTrials.gov identifier NCT01739348). 
The lack of success may relate to the timing of the intervention. Current trials 
were performed with mild to moderate dementia cases (235). However, PET 
(positron emission tomography) studies in combination with amyloid binding 
radioactive marker Pittsburgh Compound B have shown that in humans, 
β-amyloid deposition already commences decades before the manifestation of 
clinical symptoms (1,236–238). Thus, at a stage when amyloid deposition has 
already reached an asymptote of accumulation, Aβ lowering drugs might have 
no more impact. Also it is unclear whether at such a late stage Aβ-induced 
pathology is the main mediator of toxicity or whether other toxic mediators 
would even persist in the absence of amyloid pathology. The current 
consensus is that at late stage progressive pathology is already so much 
advanced that it can not be stopped anymore (239). For future AD therapy with 
Aβ lowering drugs it is therefore of utmost importance to start therapy at an 
early stage of β-amyloid pathology (240–242). 
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1.3.2 Mechanism-based side effects of BACE1 inhibition 
Besides optimizing the timing of BACE1 inhibitor treatment, one of the most 
important prerequisites for successful therapeutic application will be to 
determine the appropriate BACE1 inhibitor dosage. Bace1–/– mice display 
complex neurological phenotypes, including growth retardation (243), retinal 
pathology (244), memory deficits (220,221,245), hypomyelination (246,247), 
seizures (248–250), axon guidance defects (251–253), and schizophrenia-like 
behaviors (254). The variety of phenotypic alterations in Bace1–/– mice 
indicates that therapeutic BACE1 inhibitor treatment might cause health issues. 
However, it is unclear whether adverse effects observed in Bace1–/– mice also 
translate to humans. Bace1–/– mice completely lack BACE1 enzymatic activity 
at any developmental stage. Thus, some of the adverse effects might be due to 
a critical role of BACE1 in development and might not be relevant in adulthood. 
For example, myelination is an early process that has already completed in 
adulthood (255) and thus, characteristic hypomyelination in Bace1–/– mice 
clearly is a developmental phenotype. Such reports urge caution against 
overinterpreting the relevance of Bace1 deletion data to the outcome of 
pharmacological inhibition of BACE1. In contrary, formation of muscle spindles 
is a continuous process that occurs over the whole life span and is affected not 
only in Bace1–/– mice, but also in BACE1 inhibitor treated adult wildtype mice 
(192). Therefore, this phenotype might also occur in Alzheimer patients (167). 
Additionally, pharmacological BACE1 inhibition in adult wildtype mice induces 
rapid and prolonged decrease in spine turnover and spine density after a 
treatment period of 14 days (179,180). In light of these mechanism-based 
adverse effects of BACE1 inhibition in mice, it will be critical to minimize 
BACE1 inhibitor dosage as much as possible. However, there are clear 
indications that partial inhibition of BACE1 can be therapeutically effective, if 
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the treatment is initiated early enough. Life-long reduction of Aβ levels by 40% 
results in 5- to 7-fold reduced risk of developing AD (146) and a slight reduction 
of Aβ levels by 12% in Bace1+/– mice reduces total Aβ deposition by 50% in 
aged mice (256). Thus, moderate inhibition of BACE1 might suffice to 
effectively reduce Aβ levels and still avoid excessive mechanism-based 
adverse effects (167). In conclusion, the most challenging question for the 
clinical development of BACE1 inhibitors concerns the stage of Alzheimer’s 
disease at which to treat for optimum efficacy and the appropriate dosage that 
balances clinical safety and therapeutic efficacy. 
1.4 Intravital microscopy 
Two-photon intravital microscopy is an imaging technique that enables to 
visualize various biological processes in living organisms. The technique 
proved especially useful for the investigation of neurobiological questions. For 
example, the technique enabled for the first time to image the structural and 
functional plasticity of neuronal networks in vivo and to correlate it with 
environmental stimuli. The technical development of intravital microscopy was 
a result of innovative technical milestones in diverse scientific sectors, such as 
physics, genetics and biochemistry. 
1.4.1 Fluorescence microscopy 
Brain tissue consists of small and tightly packed biological structures. By 
applying serial section scanning microscopy, Kasthuri et al. showed that a 
1,500 µm3 cubic volume of brain tissue (equivalent to a cube of 11.4 µm edge 
length) contains 193 dendrites, 1407 axons and 1700 synapses (257). Initially, 
this dense allocation of individual substructures in brain tissue hampered 
investigating the intricate morphology of neurons. The initial breakthrough was 
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the development of silver staining by Ramón Cajal, because it allowed to 
selectively visualize separate neurons and their synapses. However, such 
sparse histochemical labelling requires chemical processing of the specimen 
and is thereby limited to post mortem tissue. The discovery of fluorescence was 
a key finding that allowed direct visualization of biological structures in living 
tissue. In 1908, August Köhler was the first to describe a new microscopical 
method „luminescence microscopy“ (258) which is nowadays known as 
fluorescence microscopy. Köhler showed that some stainings – so called 
fluorophores – emit light when excited at a certain wavelength. The spectrum of 
emitted light is shifted to longer wavelengths as compared to the excitation 
spectrum. This phenomenon was coined Stokes-shift after the discoverer 
George Stokes (259) and is illustrated in Figure 3 by a Jabloński-diagram 
(260,261). 
Upon absorption of a photon of sufficient energy by a chromophore an electron 
is excited from the lowest-energy ground state to an excited higher-energy 
state. However, this excited state is energetically unstable causing the electron 
to return to the initial ground state within 1 to 10 nanoseconds. Spontaneous 
transition from the first excited state (S1) back to the ground state (S0) 
with simultaneous emission of a photon is called fluorescence. During this 
process energy is also released by vibrational relaxation and therefore the 
emitted photon has lower energy and therefore longer wavelength as compared 
to the excitation light (Figure 3). Fluorescence microscopy has enabled to 
directly visualize certain organic compounds due to their intrinsic fluorescence. 
For example, the autofluorescence of coenzyme nicotinamide adenine 
dinucleotide (NADH) and nicotinamide adenine dinucleotide phosphate 
(NADPH) allows to determine the redox state of a cell, since the oxidized 
versions NAD+ and NADP+ show reduced fluorescence (262). Additionally, 
endogenous fluorescence of mitochondrial flavoproteins allows to measure 
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activity of neurons, since flavoproteins have green autofluorescence under 
aerobic oxidation (263). 
While the discovery of fluorescence allowed visualization of biological 
structures in the living brain it was the development of genetically encoded 
fluorophores that immensely increased opportunities to investigate biological 
processes. In 1962, the biochemist Osamu Shimomura and his colleagues 
isolated the chemiluminescent protein GFP (green fluorescent protein) from the 
jellyfish Aequorea victoria (264). 30 years later the gene for GFP could 
successfully be cloned and expressed in different species (265–267). For the 
discovery and development of GFP Osamu Shimomura, Martin Chalfie and 
Roger Y. Tsien won the nobel prize for chemistry 2008. GFP expression can be 
applied to investigate localization, interaction and dynamics of diverse proteins. 
Expression under a specific promoter allows to observe gene activity in 
individual cells (268). For the in vivo analysis of neuronal structures, transgenic 
mice have been generated that express GFP or spectral variants under control 
of specific promoters. For example, in the GFP-M mouse, enhanced GFP 
(eGFP) is expressed by the pan-neuronal promoter Thy-1.2 (269). As a result 
of random insertion of the transgene in the genome, only specific neuronal 
groups express the fluorophore. This results in a sparse labelling of individual 
neurons, similar to a Golgi staining. Another example is the VGLUT1Venus model 
which expresses the Vesicular GLUtamate Transporter 1 (VGLUT1), fused to 
the fluorescent protein Venus under VGLUT1 endogenous promoter (90). This 
model enables to visualize presynaptic boutons and is described in detail in the 
following subsection. 
Conventional fluorescence microscopy is only partially suited for intravital 
microscopy of neurons. The high lipid fraction of axonal myelin causes strong 
scattering of excitation and emission light (270), which limits optical access only 
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to the superficial cortical layer. This shortcoming was substantially improved by 
the introduction of two-photon microscopy in 1990 by Winfried Denk (271).  
1.4.2 In vivo two-photon microscopy 
The nonlinear optic effect of two-photon (2P) excitation was already postulated 
in 1931 by Maria Göppert-Mayer (272). Two-photon excitation occurs when two 
photons coincide quasi-simultaneously on a fluorescent molecule. These 
photons must have approximately twice the wavelength that is necessary for 
excitation by a single photon. The probability for non-linear excitation is very 
low, but increases proportional with the square of light intensity. Therefore, to 
obtain measurable 2P excitation high photon density in the range of several 
kW/cm2 has to be generated. Such high peak power can be obtained with 
pulsed lasers (light amplification by stimulated emission of radiation). For 
example titanium-sapphire (Ti:Sa) lasers can generate very short (<100 
femtoseconds), intensive light pulses of defined wavelength at a rate of 80 
MHz. Since the light is not emitted continuously but in the form of extremely 
short pulses, a peak power of several 100 kW can be achieved at a low mean 
power of 2.5 W. This ensures high density of photons without damaging the 
specimen. 
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Figure 3. Simplified Jabłoński-diagram for illustration of one-photon versus two-photon 
exciation for the fluorophore eGFP. For one-photon excitation a single photon (cyan wave) 
carries sufficient energy to excite the fluorophore to the excited higher-energy state S1. Upon 
transition back to the initial ground state S0, a photon of slightly lower energy as compared to 
the excitation photon is emitted (green wave). For two-photon excitation, two photons each 
confer half the energy required for one-photon excitation. This nonlinear optic effect requires 
the photons to coincide quasi-simultaneously on the fluorophore and requires high photon 
densities. Since S1 consists of different energy substates, excitation can occur within a range 
of wavelengths. While the one-photon excitation spectrum usually has one maximum, the two-
photon spectrum normally has two maxima. Adapted from Drobizhev et al. (273). 
2P microscopy has crucial advantages over conventional laser scanning 
microscopy. Due to the non-linear optical effect, fluorescence excitation is 
restricted to the focal spot which provides intrinsic optical sectioning within the 
axial dimension. In contrast to one-photon excitation – in which the whole light 
cone is excited – 2P excitation generates no out-of focus excitation. This 
minimizes photobleaching and phototoxicity. In addition, for 2P excitation 
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photons of longer wavelength and thereby lower energy can be used which is 
scattered and absorbed less in neuronal tissue and enables deeper penetration 
up to 800 µm into the brain (271,274). 
To gain optical access to the brain of mice a cranial window has to be 
implanted onto the skull. Different approaches have been described, the 
thinned skull (275) and the open skull (276) preparation. For the thinned skull 
method the skull is carefully thinned with a dental drill until only an 
approximately 20 µm thin transparent layer of skull is left. Such an optical 
window is limited in size to 0.1 to 0.3 mm2 and the remaining thin layer of skull 
causes considerable photon aberration limiting the penetration depth. For 
chronic imaging over long time periods the preparation has to be repeated due 
to regrowth of bone. In most cases this is only possible for three to four times, 
since the skull loses transparency over time. 
For the open skull preparation, a circular piece of the skull with a diameter from 
3 to 5 mm is completely removed and replaced by a glass window. This 
preparation allows chronic imaging of brain tissue up to a depth of 800 µm for 
time periods of up to more than one year (277). This approach is considerably 
more invasive than the thinned skull procedure and causes activation of 
microglia and astrocytosis. However, the immune reactions normally subside 
within 3 to 4 weeks after surgery (276). 
1.5 VGLUT1Venus mouse model 
VGLUT1Venus mice express the Vesicular GLUtamate Transporter 1, fused to 
the fluorescent protein Venus under VGLUT1 endogenous promoter (90). 
VGLUT1 is a transmembrane protein localized in presynaptic vesicles and has 
the function to uptake glutamate into these vesicles. An average synaptic 
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vesicle (Figure 4a) contains approximately 9 copies of VGLUT1 (278). Hence, 
in VGLUT1Venus mice all glutamatergic, VGLUT1 positive boutons are 
fluorescently labeled (Figure 4b). Since the fusion gene replaces VGLUT1 
through homologous recombination at the endogenous vglut1 locus the 
intensity of emitted fluorescence reflects the amount of VGLUT1 vesicles. 
VGLUT1Venus mice are viable and fertile. The fusion protein was shown to be 
fully functional in these mice, since it retains the ability to interact specifically 
with EndophilinA1 and shows the same glutamate uptake efficacy as WT 
VGLUT1 (278). 
 
Figure 4. Composition of an average vesicle synaptic vesicle. (a) An average synaptic 
vesicle contains approximately 9 copies per vesicle. The magenta arrow highlights VGLUT. 
Adapted from Takamori et al. (278). (b) Overview of VGLUT1
Venus
 fluorescence in PFA-fixed 
mouse brain. Adapted from Herzog et al. (90). 
 
26 
 
2. Results 
2.1 NB-360 reduces soluble Aβ levels 
To assess the efficacy of the BACE1 inhibitor NB-360 (233), APPPS1 mice (89) 
were fed with food pellet containing NB-360 or vehicle, starting at an age of six 
weeks. After two weeks of chronic treatment, soluble Aβ40 and Aβ42 levels 
were determined via ELISA. The age was chosen to obtain brain tissue before 
initiation of β-amyloid deposition, in order to exclude contamination by 
deposited fibrillar Aβ. NB-360 treatment reduced soluble Aβ40 and Aβ42 levels 
in the forebrain by 80% and plasma Aβ40 levels by 70% (Figure 5). 
 
Figure 5. BACE1 inhibition significantly reduces Aβ40 and Aβ42 levels. (a) Molecular 
structure of NB-360. (b) In six weeks old mice treated for 14 days ad libitum with food pellets 
containing NB-360 (0.25 g/kg) the levels of Aβ40 and Aβ42 are significantly reduced by 80% in 
forebrain and by 70% in plasma. Data presented as mean ± SEM with **p < 0.01; ***p < 0.001; 
n = 6; (t-test). 
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2.2 Concurrent imaging of β-amyloid deposition and 
synaptic pathology 
The question was addressed whether pharmacological interference with Aβ 
generation beneficially influences amyloid plaque burden and plaque-
associated synaptic pathology. For this, chronic in vivo two-photon imaging of 
Methoxy-X04 stained amyloid plaques and glutamatergic boutons was 
performed in APPPS1xVGLUT1Venus mice (Figure 6a). The somatosensory 
cortex was imaged weekly from 3 to 7 months of age and NB-360 or vehicle 
treatment was initiated at 4 months of age (Figure 6b). Individual plaques were 
tracked in consecutive imaging time points (Figure 6c). 
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Figure 6. In vivo two-photon imaging of plaques and associated synaptic pathology. (a) 
APPPS1xVGLUT1
Venus 
mice were implanted a cranial window to perform chronic in vivo two-
photon imaging of somatosensory cortex. (b) Mice were reimaged repetitively in weekly 
intervals starting from 3 months of age for up to 16 weeks. After 4 time points of baseline 
imaging mice were administered BACE1 inhibitor or vehicle food pellet. (c) In the same region 
of interest Methoxy-X04 stained β-amyloid plaques and VGLUT1
Venus
 positive glutamatergic 
boutons were repetitively imaged. 
2.3 BACE1 inhibition slows down β-amyloid deposi-
tion 
In each mouse approximately 80 plaques were analysed and time point of first 
appearance and changes in size were quantified over time (Figure 7a). As a 
result of spherical aberration, plaques seem artificially elongated in axial 
direction. Thus, for determination of plaque size the largest extension in XY of 
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each individual plaque was determined and – assuming a spherical shape of 
plaques (279) – the radius was calculated as        =      /  (Figure 7b, c). 
Subsequently, growth of individual plaques was quantified as incremental 
increase of plaque radii per week (Figure 7d). 
 
Figure 7. Procedure for determination of plaque growth kinetics. (a) Time series of 
representative 3D rendered plaques of the vehicle (light gray) and NB-360 (dark gray) treated 
cohorts. Scale bar represents 60 μm. (b,c) For the same plaques as in (a) the radii at 
consecutive time points were calculated, fitted with monophasic association functions, and (d) 
growth rates at each time point were derived. 
The sum of the volume of all plaques per time point was determined and 
divided by the total imaged brain volume to obtain the overall β-amyloid 
burden. In vehicle treated mice the β-amyloid burden increases linearly over 
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the total imaging period at a rate of 0.076% ± 0.015% brain volume occupied 
by plaques every week (Figure 8a). Pharmacological BACE1 inhibition 
significantly slowed down β-amyloid deposition by 49%. 
2.4 BACE1 inhibition most effectively lowers forma-
tion of new plaques 
β-amyloid deposition can occur either by adhesion of soluble Aβ to the surface 
of already existing plaques, resulting in plaque growth or via spontaneous 
aggregation to form new plaques. These two processes follow different kinetics 
(277) and have distinct biophysical properties (277,280–282). Therefore, it was 
important to assess whether BACE1 inhibition affects plaque formation and 
growth to a different degree. 
Over the imaging period, plaque growth slightly decreased with time in both 
cohorts (Figure 8b). Thus, the imaging period relates to the transition phase of 
β-amyloid deposition (277), when the plaque surface available for further Aβ 
accretion, starts to exceed the available levels of soluble Aβ (277,283–285). 
Apart from the age-dependent decline, BACE1 inhibition reduced plaque 
growth rates significantly. Between 1 to 10 weeks mean plaque growth was 
reduced by approximately 52% (values were normalized to week 0, Figure 8b). 
To quantify the plaque formation rate, the density of plaques was determined 
for each time point (Figure 8c) and gain of plaque density with time was 
calculated. After 8 weeks of BACE1 inhibitor treatment plaque density was 
reduced by 18.9% (values were normalized to week 0) compared to vehicle 
treatment. BACE1 inhibition significantly reduced the formation rate of new 
plaques (Figure 8d). Mean formation rate was decreased by 12-fold between 4 
to 8 weeks after treatment. 
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Figure 8. BACE1 inhibition most effectively reduces formation of new plaques. (a) 
Integrated volume fraction of all β-amyloid plaques (TWA: Fint[13] = 3.31, p < 0.001; Ftime[13] = 
35.07, p < 0.0001). Lines show linear regressions of the data (F-Test, p < 0.01). (b) Kinetics of 
mean plaque growth rates (TWA: Fint[30] =1.80, p = 0.010; Ftime[10] = 42.90, p < 0.0001). (c) 
Kinetics of mean plaque density (TWA: Fint[33] =4.41, p < 0.0001; Ftime[11] = 35.28, p < 0.0001), 
and (d) mean rate of newly formed plaques (TWA: Fint[33] = 1.65, p = 0.020; Ftime[11] = 2.05, p 
= 0.026). Data presented as mean ± SEM; n = 5-6. 
The combined effect of moderately reduced plaque growth and nearly halted 
plaque formation should also be apparent from the plaque size distribution. For 
this, plaques were grouped according to their size, and mean plaque densities 
were obtained. By comparing plaque size distributions before and at 10 weeks 
after treatment, a general shift to larger plaque sizes could be detected (Figure 
9). Most evidently, small plaques only rarely occur after BACE1 inhibition. 
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Figure 9. After BACE1 inhibition pre-existing plaques remain smaller and, less small 
plaques are detected. Frequency distribution of plaque radii at weeks 0 and 10. Reduced 
plaque formation and growth is reflected in the plaque size distribution as shift to larger radii 
and lower frequency of small plaque radii. Data presented as mean ± SEM; n = 5-6. 
2.5 BACE1 inhibition reduces plaque growth irrespec-
tive of plaque size 
We further tested whether plaques of different size might be differentially 
affected by BACE1 inhibition. For this we grouped plaques according to their 
size and obtained mean growth rates for each time point. BACE1 inhibition 
reduced plaque growth evenly, irrespective of plaque size (Figure 10a). Thus, 
once plaques had formed they constantly kept growing and did neither shrink 
nor disappear throughout the period of BACE1 inhibitor treatment. 
The volume that β-amyloid plaques occupy only partly reflects their actual 
pathological impact. With time microglia and astrocytes are recruited to amyloid 
plaques which causes secondary detrimental effects in the immediate 
environment of plaques (286,287). Therefore, in the imaged brain volume we 
measured the distance of each voxel to the closest plaque (Figure 10b). Before 
treatment initiation the mean distance to closest plaque was approximately 55 
µm and the maximal distance was 160 µm (Figure 10c). BACE1 inhibition 
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significantly slowed down the reduction in mean distance (Figure 10d) by 
48.5% (-1.03 ± 0.40 µm/week versus -0.50 ± 0.21 µm/week), indicating slower 
β-amyloid deposition. 
 
 
Figure 10. BACE1 inhibition reduces plaque growth independent of plaque size. (a) 
Growth rates of plaques of different radii before and one week after treatment initiation. (b) In 
the imaged brain volume the distance of each voxel to the closest plaque was determined via 
3D distance transformation. (c) Frequency distribution of the distance of imaged brain volume 
to the closest plaque surface at weeks 0 and 10. (d) Kinetics of mean distance of brain volume 
to closest plaque (TWA: Fint[13] =3.90, p < 0.0001; Ftime[13] = 41.14, p < 0.0001). Lines show 
linear regressions of the data (F-Test, p < 0.05). Data presented as mean ± SEM; n = 5-6. 
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2.6 Formation of new plaques is enhanced in vicinity 
to pre-existing plaques 
Previously, it was shown that BACE1 accumulates in peri-plaque dystrophic 
axons (78,81,193,194). Thus, plaques might locally enhance Aβ production 
(76) and thereby further aggravate β-amyloid deposition. To test this 
hypothesis and to investigate whether inhibition of BACE1 activity might break 
this vicious pathogenic cycle, we quantified the mean plaque formation rate 
close and distant to pre-existing plaques within 1 to 8 weeks after treatment 
start. In vehicle treated mice, the rate of plaque formation within 0-20 µm 
distance from pre-existing plaques was 4.2-fold higher as compared to the rate 
at 80-100 µm distance (Figure 11a and b). At week 10 shorter inter-plaque 
distances were significantly more frequent (Figure 11c). In BACE1 inhibitor 
treated mice, plaque formation was globally reduced, but remained 5.4-fold 
higher in proximity to plaques.  
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Figure 11. Pre-existing plaques locally enhance further formation of new plaques. (a) 
Representative image of 3D rendered plaques 10 weeks after treatment. The color map 
indicates the distance of each newly formed plaque to the closest plaque that was already 
present when the new plaque formed. White plaques were already present from the beginning. 
(b) Mean rate of plaque formation after treatment initiation at varying distances to already 
existing plaques (TWA: Fint[4] = 2.20, p = 0.089; Ftreatment[1] = 8.17, p = 0.019; Fdistance[4] = 6.17, 
p < 0.001). (c) Frequency distribution of the minimal distance between each plaque and the 
closest neighbouring plaque at 10 weeks after treatment (TWA: Fint[7] = 0.46, p = 0.863; 
Ftreatment[1] = 3.27, p = 0.104; Fdistance[7] = 52.74, p < 0.0001). Data presented as mean ± SEM; n 
= 5-6. 
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2.7 BACE1 inhibition fails to prevent BACE1 accumu-
lation in peri-plaque dystrophies 
BACE1 distribution was assessed by immunostaining in mice treated for 10 
weeks (Figure 12a). Enrichment of BACE1 was detected up to approximately 5 
µm from plaque borders (Figure 12b). Local BACE1 accumulation was already 
evident for small plaques (Figure 12c) and significantly increased with plaque 
size, reaching a maximum for plaques of 10 µm radius. BACE1 inhibition 
tended to reduce local accumulation of BACE1 but the effect was not significant 
(Figure 12c). 
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Figure 12. Inhibition of BACE1 activity does not prevent BACE1 accumulation in peri-
plaque dystrophies. (a) BACE1 immunostainings 10 weeks after treatment onset. The green 
line depicts the outer plaque border as defined by Methoxy-X04 fluorescence, and white lines 
indicate 5 µm spaced distance rings from the plaque border. Scale bar represents 10 μm. (b) 
Fraction of BACE1 immuno positive brain volume at varying distances to the closest plaque 
border for plaques of 10-20 µm radius. (c) Mean fraction of BACE1 immuno positive brain 
volume within 1 µm distance from plaque border for plaques of increasing radii (TWA: Fint[15] = 
0.20, p = 1.000; Ftreatment[3] = 1.33, p = 0.294; Fradius[5] = 14.04, p < 0.0001). Data presented as 
mean ± SEM; n = 5-6. 
2.8 BACE1 inhibition mitigates progression of presyn-
aptic pathology 
The question arose whether the beneficial impact of BACE1 inhibition on 
β-amyloid deposition would mitigate synaptic pathology. The VGLUT1Venus 
fluorescence pattern appeared punctate with small sphere-like presynaptic 
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boutons distant from plaques and large swollen axonal dystrophies in proximity 
to plaques (Figure 13a). Custom-written Matlab cluster analysis was applied for 
automated morphological segmentation. VGLUT1-positive structures became 
larger with increasing plaque size and developed within a range of up to 5-10 
µm around plaque borders (Figure 13b).  
 
Figure 13. BACE1 inhibition mitigates progressive axonal pathology. (a) VGLUT1
Venus
 
fluorescence micrographs for two plaques before and 8 weeks after treatment. (b) 
Segmentations of the respective images in (A), with color code indicating the minimal diameter 
of individual VGLUT1-positive structures. Magenta colored lines depict the outer plaque border 
and white lines indicate 5 µm spaced distance rings from plaque border. The cumulative 
distributions (below) indicate the proportion change of differently sized VGLUT1-positive 
structures with distance to closest plaque. Data presented as mean ± SEM. 
A previous publication reported that axons with severe plaque-associated 
dystrophies can develop secondary dystrophies even distant to plaques (288). 
Consistently, in 6 months old APPPS1xVGLUT1Venus mice, large VGLUT1-
positive structures emerged more frequently even distant (>30 µm) from 
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plaques as compared to wild type VGLUT1Venus mice of same age (Figure 14a). 
BACE1 inhibition had no evident impact on that specific pathology. According 
to their diameter, VGLUT1Venus-positive structures were classified either as 
boutons or axonal dystrophies. A diameter of 2.0 µm was defined as maximal 
threshold for boutons, since in wild type mice less than 1.0% of VGLUT1-
positive structures were larger. Furthermore, a diameter of 2.0 µm also 
demarked the transition size, at which VGLUT1-positive structures became 
more abundant in proximity to plaques (Figure 14b). In proximity to plaques the 
fraction of brain volume occupied by axonal dystrophies depended on plaque 
size. The corona of axonal dystrophies became denser with increasing plaque 
radius and was maximal for plaques of 10 µm radius (Figure 14c). BACE1 
inhibition tended to reduce the extent of axonal dystrophies at the plaque 
border, but this effect did not reach statistical significance. However, with time 
the total amount of plaque-associated axonal dystrophies increased at a 10-fold 
reduced rate in BACE1 inhibitor treated mice. (Figure 14d). 
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Figure 14. BACE1 inhibition mitigates progression of presynaptic dystrophies. (a) 
Cumulative distribution of VGLUT1-positive brain volume according to the diameter of 
VGLUT1-positive structures distant (>30 µm) from plaques after 8 weeks of treatment. Age-
matched, untreated VGLUT1
Venus
 mice were used as control. (b) Normalized distribution of 
VGLUT1-positive structures of distinct size. Only structures with minimal diameter from 0.8 to 
3.2 µm are shown in order to highlight the transition range. Small structures up to 1.8 µm 
diameter are abundant distant to plaques. Structures of 2.0 µm diameter or higher are 
abundant in proximity but are reduced distant to plaques (n = 10 mice, before treatment onset). 
(c) Fraction of brain volume within 1 µm distance from plaque border occupied by axonal 
dystrophies (TWA: Fint[7] = 0.43, p = 0.882; Ftreatment[1] = 0.94, p = 0.360; Fradius[7] = 6.46, p < 
0.0001). (d) Total fraction of dystrophic brain volume within 10 µm distance from plaque border 
(TWA: Fint[11] = 2.29, p = 0.016; Ftime[11] = 12.60, p < 0.0001). Lines show linear regressions of 
the data (F-Test, ns). Data presented as mean ± SEM; n = 4 vehicle, n = 6 NB-360 and n = 3 
control mice. 
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2.9 BACE1 inhibition fails to prevent plaque associ-
ated bouton loss 
The density of boutons locally decreased in proximity to plaques (Figure 15a). 
This bouton loss became more pronounced with increasing plaque radius, but 
did not differ between treatment cohorts (Figure 15b). No significant change in 
bouton density between cohorts was observed over time (Figure 15c). 
 
Figure 15. BACE1 inhibition does not prevent plaque-associated bouton loss. (a) 
Quantification of the densities of VGLUT1-positive boutons after treatment onset at varying 
distances and for plaques of varying radii. Traces were fitted with monophasic association 
functions to obtain the half-distance. (b) Toxic effect of plaques of increasing radii on bouton 
density, measured as the half-distance of monophasic association fits (TWA: Fint[4] = 0.13, p = 
0.972; Ftreatment[1] = 1.22, p = 0.302; Fradius[4] = 9.93, p < 0.0001). (c) Global bouton densities 
normalized to time points before treatment (Fint[6] = 0.76, p = 0.605; Ftime[6] = 1.95, p < 0.0921). 
Data presented as mean ± SEM; n = 4-6. 
 
42 
 
3. Discussion 
According to the prevailing theory, the amyloid cascade hypothesis, the initial 
cause for AD is the cerebral accumulation and aggregation of Aβ. Due to the 
synaptotoxic effect of these Aβ aggregates, synapses are lost and nerve cells 
degenerate which manifests in progressive cognitive decline (98,289). Based 
on this hypothesis, in the current study the impact of the Aβ lowering BACE1 
inhibitor NB-360 was tested in a transgenic mouse model of AD. 
3.1 Amyloid plaque kinetics 
At the provided dosage BACE1 inhibitor treatment reduced soluble Aβ levels in 
APPPS1 mice by 5-fold, plaque growth by 2-fold, and plaque formation by 12-
fold. The particularly strong impact of the treatment on the formation of new 
plaques might have two mechanisms. 
i. Nucleation seed formation requires a higher critical Aβ concentration than 
accretion to already existing β-amyloid fibrils (277,280–282). Thus, 
reduction of Aβ level decreases the likelihood of new plaque formation 
more strongly than plaque growth. 
ii. Accumulation of BACE1 in peri-plaque dystrophies (78,81,193,194) might 
enhance local Aβ generation (76). Indeed, our observation of increased 
plaque formation close to existing plaques, support the notion that Aβ 
generation is elevated in vicinity of plaques. Additionally, even though 
BACE1 inhibition effectively reduces BACE1 activity the treatment does not 
rescue abnormal accumulation of BACE1 in peri-plaque dystrophies. 
 
3.2 Synaptic Aβ pathology 
43 
 
Therefore, once a plaque has formed, excessive BACE1 accumulation 
amplifies local Aβ generation even when BACE1 activity is inhibited. 
Thus, at a stage when β-amyloid pathology has commenced, these 
mechanisms aggravate pharmacological intervention to block further Aβ 
deposition. Consistently, BACE1 inhibition only moderately reduces growth of 
pre-existing plaques, while plaque formation is almost halted in APPPS1 mice. 
3.2 Synaptic Aβ pathology 
BACE1 inhibitor treatment reduced the rate of presynaptic dystrophy formation 
by 10-fold, which indicates a beneficial impact on synaptic toxicity. However, 
the total density of presynaptic boutons did not significantly differ between 
treatment cohorts. There are two possible explanations for this discrepancy. In 
APPPS1 mice bouton loss is restricted to the proximity of plaques and – 
depending on plaque size – returns to normal density within 5 to 10 µm from 
plaque border. The BACE1 inhibitor treatment results in 0.5 % reduced 
β-amyloid deposition compared to vehicle treated APPPS1 mice. For detection 
of such small changes, the variability of bouton density in different mice is too 
high. Another explanation would be that the beneficial local impact of the 
treatment on plaque-associated synaptic pathology is balanced by adverse 
effects of BACE1 inhibition on synapse density (179,180). 
3.3 BACE1 inhibitor dosage 
In light of dose-dependent adverse effects of BACE1 inhibition in mice 
(179,180,290), it is critical to minimize BACE1 inhibitor dosage as much as 
possible. This particularly applies for preventive treatment that will require life-
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long drug administration, starting at an age when patients are still healthy and 
accurate prediction of AD might not always be ensured. 
Inhibition of BACE1 seems to be clinically beneficial in the context of elevated 
BACE1 and Aβ levels in brains of AD patients (195,196,200). However, the 
unequal distribution of BACE1 poses a major obstacle for pharmacological 
BACE1 inhibition. An adequate BACE1 inhibitor dosage, necessary to 
sufficiently inhibit the high BACE1 levels in peri-plaque axonal dystrophies 
(78,81,193,194), might cause excessive inhibition of physiological BACE1 
activity distant to plaques. Conversely, partial BACE1 inhibition to ensure 
physiological BACE1 activity might prevent potential mechanism-based 
adverse effects (179,180,290), but might not suffice to break the vicious cycle 
of self-sustained Aβ generation close to plaques. 
The finding of utmost susceptibility of plaque formation in response to BACE1 
inhibition, points to a therapeutical strategy that might balance potential 
adverse effects and sufficiently efficacious reduction of β-amyloid deposition. 
Such a compromise would be to aim for a BACE1 inhibitor dosage that 
prevents formation of new plaques rather than aiming for complete arrest of 
plaque growth. This strategy would be directed at delaying rather than halting 
the progression of AD at any rate. 
Since in human patients Aβ levels are generally lower as compared to APPPS1 
mice, it is important to remark that it is possible that a narrow range of BACE1 
inhibition dosage exists that is tolerable and still completely halts β-amyloid 
deposition. However, given the adverse effects in mice this might not be an 
optimal primary clinical endpoint. 
Furthermore, enhanced plaque formation rate in the vicinity of pre-existing 
plaques might be causative for the characteristic spreading of β-amyloid 
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deposition that typically initiates locally and then gradually disperses into 
adjoining unaffected brain regions (28–33). This conclusion is in agreement 
with previous studies, reporting that plaque deposition gradually invades 
grafted wt tissue in AD mice (291,292). Thus, even if halting plaque growth in 
humans might turn out to be difficult, it could suffice to abort plaque formation 
by BACE1 inhibition and thereby prevent further spreading into neighbouring 
brain regions. For translation of this pharmacological strategy into clinical 
therapy, it would be necessary to empirically determine the range of BACE1 
inhibitor dosage that effectively halts the spreading of β-amyloid deposition into 
unaffected brain regions, e.g. by PET imaging. 
3.4 Timing of pharmacological BACE1 inhibition 
The formation of new plaques typically occurs in the initial stage of β-amyloid 
progression and ultimately reaches a plateau of maximum density (31). In 
addition, experimental data from mice indicate that towards later stages new 
plaques rarely form while existing plaques continue to grow (277,279). 
In this study only a single dosage was tested at one stage of β-amyloid 
pathology. However, the key finding of differential impact on plaque formation 
and growth allows some logical assumptions on the potential outcomes of 
BACE1 inhibitor treatment applied at different dosages and at different stages 
of β-amyloid progression (illustrated in Figure 16): 
1. For primary prevention treatment, before Aβ accumulation, low BACE1 
inhibitor dosage might suffice to restrict Aβ levels below the critical 
concentration that is required for plaque-seeding. In agreement with this 
notion, life-long reduction of Aβ levels by 40% results in 5- to 7-fold reduced 
risk of developing AD (146). Additionally, a slight reduction of Aβ levels by 
 
3. Discussion 
46 
 
12% due to heterozygous expression of BACE1 reduces total Aβ deposition 
by 50% in aged Bace1+/– mice (256). Moreover, prophylactic therapy with a 
γ-secretase inhibitor results in sustained reduction of amyloid plaque 
pathology in Tg2576 mice (293). The current work and a previous 
publication (294) indicate, that plaque formation is locally enhanced at 
plaques and limited up to approximately 50 µm distance from pre-existing 
plaques. Thus, as long as β-amyloid deposition is still locally confined in the 
brain, the strategy of halting plaque formation with low BACE1 inhibitor 
dosage could still apply to suppress further spreading of β-amyloid 
pathology into yet unaffected parts of the brain. 
2. Secondary prevention treatment applies, when substantial parts of the brain 
are already affected with initial β-amyloid deposition. Under these 
conditions, β-amyloid deposition might even continue at Aβ levels below the 
critical concentration for nucleation seed formation. In addition, BACE1 
inhibition therapy has to compensate for increased Aβ generation close to 
plaques. In APPPS1 mice BACE1 inhibitor treatment nearly halts plaque 
formation and effectively slows down β-amyloid deposition with no sign of 
compensatory adaptation to the inhibitor over the 2.5 months long treatment 
period. Even more importantly, the treatment also slows down the 
progression of plaque-related axonal pathology. While these results imply 
that β-amyloid pathology can at least be delayed, previous end point studies 
in other murine AD models indicate that β-amyloid deposition might even be 
halted completely (233,234). 
3. Late-stage treatment in the saturation phase of β-amyloid deposition, might 
not be sufficient to stop disease progression. Our longitudinal in vivo 
approach shows that in APPPS1 mice, BACE1 inhibition failed to clear 
plaques that were already present at treatment initiation, and even though 
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the progression of axonal pathology was slowed down it could not be 
reverted. This might also explain the recently reported failure of the BACE1 
inhibitor verubestat in one clinical late-stage trial for the treatment of AD. 
 
Figure 16. Hypothetical model on the impact of different therapeutic BACE1 inhibitor 
approaches on the kinetics of amyloid deposition. The dashed magenta line delineates 
speculative Aβ levels. Before initial plaque deposition Aβ levels might transiently and locally 
surpass the critical concentration for plaque formation. Once formed, plaques exacerbate local 
Aβ-levels via BACE1 accumulation.  Low BACE1 inhibitor dosage starting already before 
initial amyloid deposition suffices to suppress Aβ levels constantly below the critical 
concentration for plaque seeding (cseeding).  After plaque deposition has commenced 
moderate BACE1 inhibitor doses are required to suppress Aβ levels below cseeding and 
suppressing plaque growth might only be achievable with high and probably toxic BACE1 
inhibitor dosing.  In the saturation phase, plaque deposition reaches a plateau with little 
space for beneficial influence of any BACE1 inhibitor dosage. 
3.5 Conclusion 
Altogether, the data imply that BACE1 inhibition is most effective if given as 
early as possible in the progression of β-amyloid pathology. Predictive genetic 
testing for familial AD would allow to initiate treatment already prophylactically. 
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However, the majority of AD patients lack predictive genetic markers and 
β-amyloid deposition is among the earliest pathological alterations in the AD 
brain (1). Thus, for the majority of AD patients presymptomatic diagnosis will 
even in future be limited to a stage when first plaques have already formed. 
Therefore, in this study the effect of BACE1 inhibitor treatment was tested at a 
stage, when β-amyloid deposition has already commenced but has not yet 
saturated, as can be deduced from the linear slope of β-amyloid deposition. 
The major future challenge will be to identify early AD biomarkers. Indeed, 
clinical biomarkers have already been determined that enable AD diagnosis 
several years before symptom onset (1,295), thus paving the way for 
presymptomatic treatment. 
To take advantage of the particular inhibitor susceptibility of plaque formation, 
treatment should be commenced when β-amyloid deposition is still locally 
confined in the brain. Thus, a moderate dosage of BACE1 inhibition might 
suffice to halt or at least delay the progression of β-amyloid pathology to AD. 
This treatment strategy would ensure moderate suppression of physiological 
BACE1 function (296) and thus reduces the risk of potential mechanism-based 
adverse effects (179). 
Apart from inhibiting BACE1 activity another therapeutical approach might be to 
target accumulation of BACE1 at plaques or alleviate the formation of axonal 
dystrophies. For this, it will be indispensable to understand the pathological 
mechanisms that cause axonal swelling and subsequent accumulation of 
BACE1. One possible mechanism has been brought up recently, in which Aβ 
causes microtubule disruption and motor protein mis-localization (76,77). As a 
result retrograde transport and thereby maturation of lysosomes is impaired 
(201,202) which causes BACE1 and other proteins to accumulate in peri-
plaque dystrophic neurites (76,77). It would be highly relevant to identify a 
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target within this cascade to interfere with axonal dystrophy formation and 
thereby BACE1 accumulation. A recent study has shown that swollen axonal 
varicosities are highly dynamic with strong changes of volume within weeks 
(297). Consequently, the emergence of peri-plaque axonal dystrophies seems 
to be reversible within a certain time window. A strategy that would alleviate 
axonal pathology at plaques in combination with tolerable BACE1 inhibitor 
dosage might represent an effective future therapeutic approach to interfere 
with β-amyloid progression. 
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4. Materials and Methods 
4.1 BACE1 inhibitor 
NB-360 was synthesized and kindly provided by Novartis. The pharmacologic 
properties have been characterized previously by Neumann and colleagues 
(233). Mice were fed ad libitum with food pellets containing NB-360 (0.25 g/kg) 
or control pellet. 
4.2 Transgenic mice 
All protocols and procedures involving animals were approved and conducted 
in accordance with the regulations of the Ludwig-Maximilian University and the 
Government of Upper Bavaria (Aktenzeichen 55.2-1-54-2532-62-12). 
Heterozygous APPPS1 mice co-express a human APP with the Swedish 
mutation (KM670/671NL) and a mutated PS1 (L166P) under the neuron-
specific Thy1-promoter (89). APPPS1 mice were crossbred with homozygous 
VGLUT1Venus knock-in mice that express the Vesicular GLUtamate Transporter 
1, fused to the fluorescent protein Venus under the endogenous VGLUT1 
promoter (90). Non-transgenic APPPS1–/– littermates crossed with homozygous 
VGLUT1Venus mice served as control. Mice were of both sexes and group-
housed under pathogen-free conditions until surgery, after which they were 
single-housed. 
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4.3 Statistical Analysis 
For statistical analysis, GraphPad Prism 5 (GraftPad Software, San Diego, 
California) was used. Data were tested for normality using D’Agostino-Pearson 
omnibus K2 test and Kolmogorov-Smirnov test. Intergroup comparisons were 
performed using two-tailed unpaired Student’s t-test. In the longitudinal 
measurements variables were compared across groups using two-way ANOVA 
(TWA) and p values refer to the test of interaction unless further specified. 
When treatment effects, genotype effects, time effects, interactions were found, 
post-hoc analyses were performed using Bonferroni analysis. All results are 
presented as mean ± SEM unless further specified. 
4.4 Plasma and brain homogenization and extraction  
Mice were deeply anesthetized with an intraperitoneal injection of ketamine and 
xylazine (130/10 mg/kg respectively). Blood was collected via cardiac puncture 
into EDTA tubes (BD microtainer tubes with K2EDTA #365974) on wet ice and 
was centrifuged at 1500 g for 15min at 4°C. Plasma was obtained from the 
supernatant and was frozen at -80°C. Brains were isolated, quick-frozen on dry 
ice and stored at -80°C. Frozen murine forebrains were homogenized in 9 
volumes of ice-cold Tris-buffered saline (pH 7.4) containing Complete protease 
inhibitor cocktail (Roche Diagnostics, Penzberg, Germany) using a Sonifier 450 
(Branson) and stored in aliquots at -80°C. Triton X-100 soluble Aβ was 
extracted by mixing 50 µl 2% Triton X-100 with 50 µl homogenate, incubating 
for 15 minutes on ice with vortexing, followed by ultracentrifugation at 100000 x 
g for 15 minutes. The clear supernatant was diluted to a final forebrain dilution 
of 1:100 and used for analysis. 
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4.5 Aβ quantification 
Six weeks old APPPS1 mice were treated for 2 weeks with vehicle or NB-360-
doted food pellets and were sacrificed subsequently to collect blood and brain 
samples. Aβ40 and 42 were determined in the forebrain and plasma using the 
electro-chemiluminescence immuno assay kits based on 6E10 from Meso 
Scale Discovery (Rockville, MD, USA) in either singlet or triplet format. 
Samples and standards were prepared according to the manufactures 
protocols. 
4.6 Cranial window implantation 
A cranial window was implanted over the right cortical hemisphere as 
previously reported (298,299). To minimize risk of postoperative wound 
infection, surgical tools were thermically sterilized with a table top steriliser 
(Fine Science Tools, Heidelberg, Germany). The surgery was performed with a 
SZ51 stereo microscope (Olympus, Hamburg, Germany) and a KL 1500 LED 
cold light Schwanenhals lamp (Schott, Mainz, Germany). Mice were 
anesthetized with an intraperitoneal injection of ketamine/xylazine (130 mg/kg 
ketamine and 10 mg/kg xylazine in 0,9% NaCl). Anesthesia depth was 
surveilled by testing the interdigital reflex. After adequate anesthesia was 
achieved, dexamethason was intraperitoneally administered (6 mg/kg in 0,9% 
NaCl) as anti-inflammatory to prevent the development of cerebral oedema 
during trepanation of the skull. Additionally, to circumvent postoperative pain 
and inflammation, the mice were administered a subcutaneous injection of the 
analgesic carprophen (7,5 mg/kg in 0,9% NaCl) and the antibiotic cefotaxim 
(250 mg/kg in 0,9% NaCl). Subsequently, mice were placed on a heating plate 
(Fine Science Tools, Heidelberg, Germany) to keep body temperature during 
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the surgery constant at 37°C. The mouse head was fixated with a MA-6N 
holder (Narishige, Tokyo, Japan) and the eyes were protected from dehydration 
by applying bepanthene ointment. Fur of the skull was disinfected with 70% 
ethanol and the scalp was removed with a scissor, without damaging the 
temple muscle. Loose hair at the wound margin was removed with a sterile 
cotton swab and the periosteum was removed with a scalpel. To reinforce 
adhesion of dental cement to the skull, a thin layer of Cyano-Veneer liquid glue 
(Hager und Werken, Duisburg, Germany) was applied on the wound margin 
and the exposed skull. Subsequently, a circular trepanation of the skull of 5 mm 
diameter was applied with a C1-Master dental drill (Schick Dental, 
Schemmerhofen, Germany) above the somatosensory cortex (stereotactic 
coordinates relative to Bregma: 2 mm caudal und 2,5 mm lateral). Particles of 
bone were removed with an electric vacuum pump. A drop of PBS was put on 
the craniotomy to prevent that the cortex dries after opening of the skull. Then 
the bone was carefully lifted with curved forceps. Slight bleedings were 
staunched by rinsing with PBS and application of hemostatic gelfoam (Pfizer, 
New York, USA). Subsequently, a round coverslip of 5 mm diameter (Fine 
Science Tools, Heidelberg, Germany) was implanted above the craniotomy and 
PBS was removed with sterile Sugi absorbent swabs (Kettenbach, Eschenburg, 
Germany). The gap between cover slip and margin of the skull was sealed with 
histoacryl tissue adhesive (B. Braun Melsungen AG, Melsungen, Germany) and 
the skull was covered with dental cement (Cyano-Veneer; Hager Werken, 
Duisburg, Germany). To allow repositioning of the mouse during subsequent 
imaging sessions a metal bar was attached to the skull and was fixated with 
dental cement. Until the moment of awakening the animal was placed on a 
heating pad and was subsequently transferred back to the home cage. 
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Table 1. Materials for cranial window implantation. 
Product Manufacturer 
Ketamine 10 % WDT, Garbsen 
Xylazine Bayer HealthCare, Leverkusen 
Dexamethasone Sigma-Aldrich, Taufkirchen 
Rimadyl (active agent Carprofen) Pfizer, Berlin 
Cefotaxim Pharmore, Ibbenbüren 
Isoflurane (Forene) Abbott, Wiesbaden 
Inhalation anaesthetic set Trajan808 Dräger Medical, Lübeck 
Gas mask for mice Custom-made 
Heating plate fore mice FST, Heidelberg 
Mouse holder for surgery Custom-made 
Bepanthene Bayer HealthCare, Leverkusen 
Stereo microscope SZ51 Olympus, Hamburg 
Table top sterilizer FST 250 Hot Bead Sterilizer FST, Heidelberg 
Drill C1 Master Schick Dentalgeräte, Schemmerhofen 
Drill head Gebrüder Brasseler, Lemgo 
Vacuum suction device Custom-made 
Syringe 1ml VWR, Ismaning 
Cannula 27G/20G VWR, Ismaning 
Ethanol (70%) Sigma-Aldrich, Taufkirchen 
Surgical tools (scissors & forceps) FST, Heidelberg 
Scalpel Swann-Morton, Sheffield, UK 
Cotton swab, sterile Paul Böttger, Bodenmais 
Hemostatic gelfoam Pfizer, Berlin 
Absorbent swabs Sugi, sterile Kettenbach, Eschenburg 
Cover slips (5 mm diameter) Gerhard Menzel, Braunschweig 
Dental adhesive Cyano-Veneer Starter Kit Hager & Werken, Duisburg 
Titanium-bar Custom-made 
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4.7 Immunohistochemistry 
Deeply anesthetized mice (130/10 mg/kg b.w. ketamine/xylazine i.p. 
WDT/Bayer Health Care) were perfused with phosphate-buffered saline (PBS) 
followed by 4% formalin solution. Mouse brains were dissected and post-fixed 
in 4% formalin for 24 hours. Fixed brains were cut into coronal 50 μm thick 
sections on a vibratome (VT1000S, Leica). Brain slices were permeabilized for 
2 hours with 1% Triton X-100 and 10% normal goat serum (Sigma-Aldrich) in 
PBS. Slices were then incubated with rabbit polyclonal antibody directed 
against BACE1 (1:1000; BACe–Cat1) (194) in 0.5 % Triton X-100 for 2 days at 
4 °C. Sections were washed in PBS and incubated with the secondary antibody 
coupled to Alexa633 (anti-rabbit 1/500, Invitrogen) 2 h at RT. To detect amyloid 
fibrils slices were incubated for 15 min with 10 µg/mL Methoxy-X04 in 50% 
ethanol and washed three times with 50% ethanol at RT. Sections were finally 
washed for 5 times 10 min with PBS before mounting them on glass coverslips 
with fluorescence conserving media (Dako). 
4.8 Microscopy 
4.8.1 Confocal microscopy 
Images were acquired with an inverse LSM 780 confocal microscope (Zeiss) 
equipped with a 40x/1.4 oil immersion objective. Excitation wavelengths were 
405 and 561 nm, emission was collected at 410–580 nm for Methoxy-X04 and 
585–735 nm for BACE1. In each mouse brain 3-dimensional 16 bit data stacks 
of 1024 x 1024 x 100 pixels were acquired from 20 different positions in the 
somatosensory cortex at a lateral resolution of 0.1 um/pixel and an axial 
resolution of 0.2 µm/pixel. 
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4.8.2 Chronic two-photon in vivo imaging 
In vivo two-photon imaging was started after a recovery period of 3-4 weeks. 
For amyloid staining Methoxy-X04 (301) was intraperitoneally injected 24 h 
before imaging at a dose of 0.5 mg/kg body weight. Throughout the imaging 
sessions, mice were anesthetized with isoflurane (1% in 95% O2, 5% CO2, 
Forene®, Abbott), placed on a heating pad to keep body temperature at 37°C 
(Fine Science Tools GmbH) and fixed to a custom-made holder using the glued 
metal plate. In vivo two-photon imaging was performed on a LSM 7 MP (Carl 
Zeiss) equipped with standard photomultiplier detectors and a 20x water-
immersion objective (W Plan-Apochromat 20x/1.0 DIC, 1.0 NA, Carl Zeiss). For 
each mouse, one region of interest was reimaged at a weekly interval. In each 
imaging session two data stacks were obtained consecutively. To resolve the 
presynaptic boutons, a high-resolution 3D stack was obtained from the 
VGLUT1Venus fluorescence in cortical layer I at a resolution of 0.08x0.08x0.4 
µm3 and dimensions of 283x283x60 µm3. Subsequently a larger but less 
resolved 3D stack was obtained from the Methoxy-X04 fluorescence at a 
resolution of 0.24x0.24x0.4 µm3 and dimensions of 425x425x200 µm3. 
Methoxy-X04 was excited at 750 nm by a Ti:Sa laser (MaiTai DeepSee, 
Spectra-Physics) and emission was collected below 485 nm. VGLUTVenus was 
excited at 915 nm and emission was collected from 470 to 550 nm. For both 
stacks the autofluorescence was recorded simultaneously at an emission range 
from 590 to 650 nm. In subsequent imaging sessions, the previously imaged 
volumes were identified by eye using the unique blood vessel pattern. This 
allowed a precise alignment of the same imaging volumes. The laser intensity 
was adjusted to keep the emitted fluorescence stable at different depths using 
the z-correction tool in the microscope control software and also at subsequent 
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imaging sessions. All images were of optimal quality and did not suffer from 
motion artefacts due to breathing or heart beating of the animal. 
Table 2. Imaging settings for acquisition of Methoxy-X04 and VGLUT1
Venus
 fluorescence. 
 Methoxy-X04 VGLUT1Venus 
Excitation wavelength 750 nm 915 nm 
Pixel size 1800 x 1800 x 501 3600 x 3600 x 151 
Image size 425 µm x 425 µm x 200 µm 283 µm x 283 µm x 60 µm 
Resolution 0.24 µm x 0.24 µm x 0.4 µm 0.08 µm x 0.08 µm x 0.4 µm 
Pixel dwell time 0.45 µs (no average) 0.45 µs (average 2x) 
Emission channels SP 485 & BP 590-650 SP BP470-550 & BP 590-650 
4.9 Data analysis of 3D microscopical data 
All data stacks obtained by in vivo two-photon microscopy were deconvoluted 
using AutoQuant (AutoQuantX3, Media Cybernetics). For quantification amyloid 
plaques, presynaptic boutons, presynaptic dystrophies as well as BACE1 
positive dystrophies, the 3D data stacks of fluorescence intensity were 
analysed using custom-written Matlab software. Initially, local background 
subtraction was performed to diminish intensity variations among different 
stacks. Subsequently, a percentile based intensity threshold was applied, and a 
connected component analysis was used to identify contiguous clusters of 
voxels. This standard analysis was slightly modified for each of the biological 
readouts with the detailed analysis described below. 
To define BACE1 positive dystrophies the 50th percentile of immuno-
fluorescence signal was used as threshold for each image stack. Connected 
component analysis was applied to identify clusters of contiguous voxels and 
clusters smaller than 1 µm3 were excluded. 
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For data stacks of VGLUT1Venus fluorescence the 75th percentile was used as 
threshold. Due to the dense arrangement of VGLUT1-positive structures 
applying that threshold results in a web-like mask of supra-threshold voxels 
with nearby structures still merging into one another. Therefore, the data was 
further segmented morphologically by calculating the distance transformation, 
followed by watershed segmentation along minimal distance ridges. 
Subsequently, the minimal diameter as well as the distance to the closest 
plaque was obtained for each segment. To analyse the distribution of minimal 
diameter of VGLUT1-positive structures as a function of plaque distance and 
plaque size, the minimal diameter was binned into 0.2 µm steps. Synapse 
densities in relation to the distance from plaques were fitted using one-phase 
association curves. 
 Y(d) = Y0 + (Plateau – Y0) * (1 – e –K * d) , with d = distance to closest 
plaque and Y = bouton density 
The half-distance (ln(2) / K) was obtained as a measure for the sphere of toxic 
influence of plaques on bouton density. 
Amyloid plaques were identified applying the 90th percentile on the Methoxy-
X04 fluorescence intensity data. Since amyloid burden typically constitutes 1 to 
2 % of brain volume in the imaged region of APPPS1 mice, this threshold is 
intentionally set to a very low level. It allows to obtain the total size of amyloid 
plaques as opposed to thresholding operations such as using local contrast or 
half-width intensity that rather detect the dense plaque core. Subsequently, 
individual amyloid plaques were tracked over time. For this purpose the image 
data from consecutive time points was loaded as time series in Imaris (Version 
7.7.2, Bitplane). Plaque volumes were extracted by 3D-surface-rendering and 
were semi-automatically tracked over time using the surface tracking module of 
Imaris. To identify nucleation events, plaques were tracked back to the first 
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time point of appearance and were only assessed when present for at least 3 
weeks to warrant unambiguous distinction from background signal. Therefore, 
quantification of plaque density and formation only include values up to 8 
weeks post-treatment even though imaging was performed up to 10 weeks. 
Correct tracking was manually checked for each amyloid plaque. For reliable 
determination of the actual size of each amyloid plaque the largest extension in 
XY was determined and the radius was calculated as        =      /  
assuming a spherical shape of plaques (279). The radii of individual plaques 
were fitted with a monophasic association function, and the radial growth rate 
at each time point was obtained by calculating the first derivative of the best fit. 
All plaques contacting the image border were excluded from the analysis. The 
distribution of presynaptic boutons, presynaptic dystrophies and BACE1 
positive dystrophies was analysed with regards to proximity to the closest 
amyloid plaque. For this purpose, a quasi euclidean 3D distance transformation 
was performed to identify the distance of every voxel to the closest plaque 
border. Distance was calculated at 1 µm resolution from the outer border of 
plaques into surrounding tissue as well as towards the inside of each plaque. 
Voxels inside plaques were assigned negative distance from plaque border. To 
quantify the pathological impact of each plaque separately, the 3D volume was 
divided into sectors with all voxels closest to a particular plaque constituting the 
sector of that plaque. 
For the correlation of plaque formation rate with plaque distance the distance to 
the closest already existing plaque was determined for each formation event at 
the respective time point of formation. For the analysis all plaques formed after 
treatment onset were pooled and closest plaque distance was binned into 20 
µm segments. For the frequency distribution of minimal inter-plaque distance, 
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the distance to the closest plaque was determined for all plaques at week 10, 
and inter-plaque distance was binned in 20 µm segments. 
4.10 Software 
Table 3. Software 
Program Manufacturer 
Adobe Illustrator CS5 Adobe Systems 
Adobe Photoshop CS5 Adobe Systems 
Adobe Indesign CS5 Adobe Systems 
AutoQuant X3 Media Cybernetics 
Imaris 7.7.2 Bitplane Imaris 
LSM Image Browser 4.2.0 Zeiss 
MATLAB 2015b MathWorks 
Microsoft Excel 2010 Microsoft 
Microsoft Word 2010 Microsoft 
GraphPad PRISM 5 Graphpad Software 
Zen 2009 Zeiss 
4.11 VGLUT1Venus signal segmentation 
Custom-written Matlab cluster analysis was applied for automated 
morphological segmentation of VGLUT1Venus fluorescence 3D stacks. 
% VglutGreen: 3D-image of VGLUT1-Venus fluorescence intensity after deconvolution 
and background correction 
% Exclude: 3D-Mask specifying parts located outside brain 
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% Res: Resolution in all three dimensions 
% VglutRed: 3D-image of autofluorescence after deconvolution and background 
correction 
  
function 
[BoutonList,BoutonIds,Dystrophies2,Dystrophies2Radius,VglutGreen,GRratio]=VglutV
enusSegmentation(VglutGreen,Exclude,Res,VglutRed) 
  
Pix=size(VglutGreen).'; % Determine pixel dimension of 3D-image 
Um=Pix.*Res; % Determine size in µm of 3D-image 
  
[Threshold]=prctile_2(VglutGreen,75,Exclude==0); % Calculate 75th percentile as 
threshold for selecting VGLUT1-Venus positive part of 3D-image 
clear Exclude; 
Mask=VglutGreen>Threshold; 
  
[Mask]=removeIslands_3(Mask,4,[0;0.025],prod(Res(:))); % Excluded voxels that are 
entirely enclosed by included voxels are detected and included to account for noise 
Distance=distanceMat_4(logical(1-Mask),'DistInOut',Res,0.1,1,0,0); % Apply 3D 
distance transformation to calculate the distance of each voxel to the outer surface of 
the VGLUT-Venus positive mask 
clear Mask; 
  
Watershed=uint8(10)-uint8(Distance); % Voxels that are located more than 1 µm (10 * 
0.1 µm) from outer border of VGLUT1-Venus positive mask are set to maximally 1 µm. 
This is necessary to avoid oversegmentation 
Watershed=single(watershed(Watershed,26)); % 3D segmentation of VGLUT1-Venus 
positive mask. The algoryhtm separates clusters of contiguous voxels along the ridge 
lines obtained from 3D distance transformation 
Watershed(Distance==0)=0; 
  
BW=bwconncomp(logical(Watershed),6); % Detect connected components (clusters) 
clear Watershed; 
Table=table(cellfun(@numel,BW.PixelIdxList).',BW.PixelIdxList.','VariableNames',{'Nu
mPix','IdxList'});  
Table.ID=(1:size(Table,1)).'; 
Table.Volume=Table.NumPix*prod(Res(1:3)); % calculate Volume in µm^3 of each 
cluster 
Wave1=struct2table(regionprops(BW,'Centroid')); 
Table.Centroid=Wave1.Centroid; % calculate center of mass of each cluster 
Table.Centroid(:,1:3)=Table.Centroid(:,[2,1,3]); 
Table.XYZum(:,1:3)=Table.Centroid.*repmat(Res.',[size(Table,1),1]); 
Table.XYZum=Table.XYZum-repmat(Um.'/2,[size(Table,1),1]); 
  
BoutonIds=labelmatrix(BW); % generate 3D image mask assigning each voxel the ID 
of the cluster that it belongs to 
clear BW; 
  
% Calculate maximal area in XY. Due to the strong spherical aberration of two-photon 
microscopy small VGLUT1-Venus positive structures (synapses) appear as elongated 
ellipses with approximately 3 times the diameter in axial as compared to lateral 
direction. Therefore maximal area in XY is used to obtain radius of each cluster 
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Wave1=accumarray_8({BoutonIds;repmat(permute(1:Pix(3),[1,3,2]),[Pix(1),Pix(2),1])},
ones(Pix.','uint8'),@sum,'2D'); 
Table.AreaXY=max(double(Wave1),[],2)*prod(Res(1:2)); 
Wave1=accumarray_8(BoutonIds,Distance,@max); 
Table.DistInMax(Wave1.Roi1,1)=double(Wave1.Value)/10; 
  
% Generate 3D-image in which each voxel is assigned the minimal radius of the 
cluster that it belongs to. The minimal radius is the minimal distance value obtained 
after 3D distance transformation. 
Wave1=uint16(Table.DistInMax*10); 
Wave1=Wave1(BoutonIds(BoutonIds>0)); 
Dystrophies2Radius=BoutonIds; 
Dystrophies2Radius(BoutonIds>0)=Wave1; 
Dystrophies2Radius=uint16(Dystrophies2Radius); 
  
% Equivalent to the previous definition of "Dystrophies2Radius" another 3D-image is 
generated in which each voxels is assigned the maximal volume of the cluster that it 
belongs to 
Wave1=uint16(ceil(Table.Volume)); 
Wave1=Wave1(BoutonIds(BoutonIds>0)); 
Dystrophies2=BoutonIds; 
Dystrophies2(BoutonIds>0)=Wave1; Dystrophies2=uint16(Dystrophies2); 
  
% Determine the maximum VGLUT1-Venus intensity value of each cluster 
Wave1=accumarray_8(BoutonIds,VglutGreen,@max); 
Table.VglutGreenMax(Wave1.Roi1,1)=Wave1.Value; 
Table.VglutGreenHWI=uint16(Table.VglutGreenMax/2); 
  
% Use the half-width intensity of each individual cluster to narrow down the size of 
each cluster 
Wave1=Table.VglutGreenHWI(BoutonIds(BoutonIds>0)); 
VglutGreenHWIbackground=BoutonIds; 
VglutGreenHWIbackground(BoutonIds>0)=Wave1; 
VglutGreenHWIbackground=uint16(VglutGreenHWIbackground); 
VglutGreenHWIbackground=VglutGreen<VglutGreenHWIbackground; 
BoutonIds(VglutGreenHWIbackground==1)=0; 
clear VglutGreenHWIbackground; 
  
% After applying half-width intensity to norrow down the total size of VGLUT1-Venus 
positive clusters obtain the radius of each cluster from maximal area in lateral 
directions. 
Wave1=accumarray_8({BoutonIds;repmat(permute(1:Pix(3),[1,3,2]),[Pix(1),Pix(2),1])},
ones(Pix.','uint8'),@sum,'2D'); 
Table.AreaXYHWI=max(double(Wave1),[],2)*prod(Res(1:2)); 
  
% Calculate the minimum value of 3D distance transformation for each cluster 
Wave1=accumarray_8(BoutonIds,Distance,@min); 
clear Distance; 
Table.DistInMin(Wave1.Roi1,1)=double(Wave1.Value)/10; 
Table.DistInDiff=Table.DistInMax-Table.DistInMin; 
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% Determine the volume of each VGLUT1-Venus positive cluster after applying half-
width intensity as limiting criterium. 
Wave1=accumarray_8(BoutonIds,ones(Pix.','uint8'),@sum); 
Table.VolumeHWI(Wave1.Roi1,1)=double(Wave1.Value)*prod(Res(:)); 
  
% For each cluster calculate the mean intensity of VGLUT1-Venus, autofluorescence 
and the ratio between both (GRratio). 
GRratio=uint16(single(VglutGreen)./single(VglutRed)*2000); 
IntensityData={'VglutGreen',VglutGreen;'VglutRed',VglutRed;'GRratio',GRratio}; 
clear VglutRed; 
for m=1:size(IntensityData,1) 
   Wave1=accumarray_8(BoutonIds,IntensityData{m,2},@mean); 
    Table{Wave1.Roi1,[IntensityData{m,1},'Mean']}=Wave1.Value; 
end 
clear IntensityData; 
% Obtain relevant information on VGLUT1-Venus positive clusters as table. 
BoutonList=Table(:,{'ID','XYZum','AreaXY','AreaXYHWI','Volume','VolumeHWI','DistIn
Min','DistInMax','DistInDiff','VglutGreenMax','VglutGreenHWI','VglutGreenMean','Vglut
RedMean','GRratioMean','Centroid','NumPix'}); 
  
% Generate a 3D-image in which each Cluster-ID is assigned a random value 
between 2 and 256. This allows for visual quality control when monitoring the data in 
Imaris. 
Wave1=find(BoutonIds==0); 
BoutonIds=(double(BoutonIds)-floor(double(BoutonIds)/256)*256); 
BoutonIds(Wave1)=0; 
  
%% subfunction 
% Calculates the percentile for a 3D-image. 
% Inside: If necessary a 3D mask of type logical  can be used to limit the calculation to 
all voxels ascribed the value 1. 
function [Result]=prctile_2(Data,Percentiles,Inside) 
Data=Data(:); 
if exist('Inside')==1 
    Inside=Inside(:); 
    Data=Data(Inside==1,:); 
end 
Data=sort(Data); 
  
Ind=round(size(Data,1)*Percentiles/100); 
Ind(Ind==0)=1; 
if isempty(Data) 
    Result=nan(size(Percentiles,1),1); 
else 
    Result=Data(Ind); 
end 
  
  
%% subfunction 
% In a 3D-mask of type logical "Islands" are identified. These are clusters of voxels 
with value 0 that are entirely enclosed by voxels of value 1. 
% MinMaxVolume: can be applied to limit the allowed volume of detected "Islands" 
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% In the output "Data3D" all detected Islands are set to value 1. 
function 
[Data3D,Islands]=removeIslands_3(Data3D,Connectivity,MinMaxVolume,Res3D) 
Pix=size(Data3D).'; 
BW=bwconncomp(1-Data3D,Connectivity); 
  
Table=table; 
Table.NumPix=cellfun(@numel,BW.PixelIdxList).'; 
Table.IdxList=BW.PixelIdxList.'; 
Table.Volume=Table.NumPix*Res3D; 
Wave1=struct2table(regionprops(BW,'BoundingBox')); 
Table.BoundingBox(:,1:6)=Wave1.BoundingBox; 
clear BW; 
if exist('MinMaxVolume')==1 
    Table=Table(Table.Volume>=MinMaxVolume(1) & 
Table.Volume<MinMaxVolume(2),:); 
end 
Table.BoundingBox(:,1:3)=Table.BoundingBox(:,1:3)+0.5; 
Table.BoundingBox(:,4:6)=Table.BoundingBox(:,1:3)+Table.BoundingBox(:,4:6)-1; 
Wave1=[1,1,1,Pix.']; 
Table.BoundingBox=Table.BoundingBox-repmat(Wave1,[size(Table,1),1]); 
if Connectivity==4 
    Table.BorderTouch=min(abs(Table.BoundingBox(:,[1,2,4,5])),[],2)==0; 
else 
    Table.BorderTouch=min(abs(Table.BoundingBox),[],2)==0; 
end 
Table=Table(Table.BorderTouch==0,:); 
Islands=zeros(size(Data3D),'uint8'); 
Islands(cell2mat(Table.IdxList))=1; 
Data3D(Islands==1)=1; 
  
%% subfunction 
% Calculates 3D distance transformation with anisotropic resolution 
function 
[DistInOut,Membership,Dist2Border]=distanceMat_4(Data3D,Output,Res,UmBin,OutC
alc,InCalc,ZeroBin,DistanceBitType) 
  
if exist('ZeroBin','var')==0 
    ZeroBin=50; 
end 
if exist('DistanceBitType','var')==0 
    DistanceBitType='uint8'; 
end 
if exist('OutCalc')~=1 
    OutCalc=0; 
end 
if exist('InCalc')~=1 
    InCalc=0; 
end 
if exist('Output')~=1 
    Output={'DistInOut';'Membership';'Dist2Border';}; 
end 
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if ischar(Output) 
    Output={Output}; 
end 
  
if exist('UmBin')~=1 || isempty(UmBin) 
    UmBin=1; 
end 
Pix=[size(Data3D,1);size(Data3D,2);size(Data3D,3)]; 
if exist('Res')~=1 
    Res=Um./Pix; 
end 
if exist('ResCalc')~=1 
    ResCalc=min(Res(:)); 
end 
PixCalc=round(Pix.*Res/ResCalc); 
  
Xi=round(linspace(1,Pix(1),PixCalc(1))); 
Yi=round(linspace(1,Pix(2),PixCalc(2))); 
Zi=round(linspace(1,Pix(3),PixCalc(3))); 
Xt=round(linspace(1,PixCalc(1),Pix(1))); 
Yt=round(linspace(1,PixCalc(2),Pix(2))); 
Zt=round(linspace(1,PixCalc(3),Pix(3))); 
  
Dist2Border=[]; 
DistInOut=[]; 
Membership=[]; 
  
if strfind1(Output,'Membership',1) 
end 
  
cprintf('text','DistanceTransform: '); 
Data3D=Data3D(Xi,Yi,Zi); 
if OutCalc==1 
    if strfind1(Output,'DistInOut',1) && strfind1(Output,'Membership',1) 
        [DistInOut,Membership]=bwdist(Data3D,'quasi-euclidean'); 
    elseif strfind1(Output,'DistInOut',1) 
        [DistInOut]=bwdist(Data3D,'quasi-euclidean'); 
    elseif strfind1(Output,'Membership',1) 
        [Membership]=bwdist(Data3D,'quasi-euclidean'); 
    end 
    if strfind1(Output,'DistInOut',1) 
        DistInOut=cast(ceil(DistInOut(Xt,Yt,Zt)*ResCalc/UmBin),DistanceBitType); % 
convert pixel based distance into µm based distance 
    end 
    if strfind1(Output,'Membership',1) 
        Membership(:)=Data3D(Membership(:)); 
        Membership=cast(Membership(Xt,Yt,Zt),DistanceBitType); 
    end 
end 
if InCalc==1 && strfind1(Output,'DistInOut',1) % inside 
    Data3D=logical(Data3D)==0; % invert so that everything outside plaque is set to 1 
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    [DistIn]=bwdist(Data3D,'quasi-euclidean'); % make distance transform for inside and 
store in Stack 
    DistIn=cast(ceil(DistIn(Xt,Yt,Zt)*ResCalc/UmBin),DistanceBitType); 
end 
clear Data3D; 
if strfind1(Output,'DistInOut',1) 
    if OutCalc==1 && InCalc==1 
        DistInOut=DistInOut+ZeroBin-(DistIn-UmBin); 
    elseif OutCalc==1 && InCalc==0 
        DistInOut=DistInOut+ZeroBin; 
    elseif OutCalc==0 && InCalc==1 
        DistInOut=DistIn+ZeroBin; 
    end 
    clear DistIn; 
end 
if strfind1(Output,'Dist2Border') 
    Dist2Border=zeros(PixCalc(1),PixCalc(2),PixCalc(3),DistanceBitType); 
    Dist2Border(1,:,:)=1; Dist2Border(end,:,:)=1; Dist2Border(:,1,:)=1; 
Dist2Border(:,end,:)=1; Dist2Border(:,:,1)=1; Dist2Border(:,:,end)=1; 
    Dist2Border=bwdist(Dist2Border,'quasi-euclidean'); % make distance transform for 
inside and store in Stack 
    Dist2Border=(cast((Dist2Border-1)*ResCalc/UmBin,DistanceBitType)); 
    Dist2Border=Dist2Border(Xt,Yt,Zt,:); 
end 
cprintf('text','\n'); 
  
%% subfunction 
% Calculates the function specified in "Function" for all individual rois specified in 
"Rois" 
function 
[Output]=accumarray_8(Rois,Data,Function,OutputFormat,AccumMethod,CountInstan
ces) 
  
if exist('OutputFormat')~=1 
    OutputFormat='Table'; 
end 
  
if istable(Rois) 
    Wave1=table; 
    for m=1:size(Rois,2) 
        Wave1.Data(m,1)={Rois{:,m}}; 
    end 
    Wave1.Name=Rois.Properties.VariableNames.'; 
    Rois=Wave1; 
    clear Wave1; 
elseif isnumeric(Rois) 
    Wave1=table; 
    Wave1.Data(1)={Rois}; 
    Wave1.Name(1)={'Roi1'}; 
    Rois=Wave1; 
    clear Wave1; 
elseif iscell(Rois) 
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    Rois=array2table(Rois,'VariableNames',{'Data';'Name'}); 
end 
RoiNumber=size(Rois,1); 
  
for Row=1:size(Rois,1) 
    [Rois.Unique{Row},~,Rois.Data{Row}]=unique(Rois.Data{Row}); 
    Max=max(Rois.Data{Row}); 
    if Max<=255 
        Rois.Data{Row}=uint8(Rois.Data{Row}); 
    elseif Max<=65535 
        Rois.Data{Row}=uint16(Rois.Data{Row}); 
    elseif Max<=2^32-1 
        Rois.Data{Row}=uint32(Rois.Data{Row}); 
    else 
        keyboard; 
    end 
    Rois.Digits(Row,1)=size(num2str(round(Max)),2); 
end 
  
TotalDigits=sum(Rois.Digits); 
Pix=size(Rois.Data{1,1}).'; 
Roi=zeros(Pix.','uint64'); 
  
for Row=1:size(Rois,1) 
    Roi=Roi+uint64(Rois.Data{Row,1})*10^sum(Rois.Digits(Row+1:end)); % donot use 
double, otherwise weird summation problems!!!, rather try uint64 
end 
  
if max(Roi(:))==uint64(2^64); keyboard; end; 
SparseRoi=Roi; 
[UniqueRoi,~,Roi]=unique(Roi); 
Rois(:,'Data') = []; 
if isempty(Data) 
    Data=[]; % in case an empty table is transferred 
    Data=[{ones(Pix.','uint8'),'Count'};Data]; 
elseif isnumeric(Data) 
    Data={Data}; 
elseif istable(Data) 
    clear Wave1; 
    if exist('CountInstances')==1 && strcmp(CountInstances,'CountInstances') 
        Data.CountInstances(:,1)=1; 
    end 
    for m=1:size(Data,2) 
        Wave1(m,1)={Data{:,m}}; 
    end 
    Wave1(:,2)=Data.Properties.VariableNames.'; 
    Data=Wave1; 
    clear Wave1; 
end 
  
if size(Data,2)==1 
    Data(:,2)=strcat('Value',num2strArray_3((1:size(Data,1).'))); 
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end 
  
Data=array2table(Data,'VariableNames',{'Data';'Name'}); 
  
if exist('AccumMethod')~=1 
    AccumMethod='NonSparse'; 
end 
Output=table; 
for Row=1:size(Data,1) 
    if strcmp(Data.Name{Row,1},'CountInstances') 
        Function=@nansum; % donot set back because is anyways the last Dataset 
    end 
     
    if strcmp(AccumMethod,'Sparse') 
        keyboard; % attention! zero values in AccumArray are excluded!!!! 
        
AccumArray=accumarray(double(Roi(:)),full(double(Data.Data{Row,1}(:))),[],Function,[]
,true); 
        Ind=find(AccumArray); 
    elseif strcmp(AccumMethod,'NonSparse') 
        
AccumArray=accumarray(double(Roi(:)),full(double(Data.Data{Row,1}(:))),[],Function); 
        Ind=(1:size(AccumArray,1)).'; 
    end 
    if Row==1 
        Output.LinRoi=Ind; 
        Output{:,Data.Name{Row}}=AccumArray(Ind); 
    else 
        [~,Wave1]=ismember(Ind,Output.LinRoi); 
        ZeroInd=find(Wave1==0); 
        Wave1(ZeroInd)=(size(Output,1)+1:1:size(Output,1)+size(ZeroInd,1)); 
        Output.LinRoi(Wave1,1)=Ind; 
        Output{Wave1,Data.Name{Row}}=AccumArray(Ind); 
    end 
    clear AccumArray; 
end 
  
Output.LinRoi=UniqueRoi(Output.LinRoi); 
for m=1:RoiNumber 
    MinMax=[sum(Rois.Digits(m+1:end))+1;sum(Rois.Digits(m:end))]; 
    Wave1=getNthNumeric(Output.LinRoi,MinMax); 
    Wave1=Rois.Unique{m}(Wave1); 
    Output{:,Rois.Name{m}}=Wave1; 
end 
clear Roi; clear Data; 
  
if strcmp(OutputFormat,'2D') 
    keyboard; 
    OrigOutput=Output; 
    Output=zeros(0,0,'uint32'); 
    for m=1:max(OrigOutput.Roi2) 
        Ind=find(OrigOutput.Roi2==m); 
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        Output(OrigOutput.Roi1(Ind),m)=OrigOutput.Value(Ind); 
    end 
end 
Output(:,'LinRoi')=[]; 
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8. Abbreviations 
°C degree celcius 
µg microgram 
µL microliter 
µm micrometer 
Aβ amyloid-β peptide 
AD Alzheimer’s disease 
ADAM10 
a disintegrin and metalloproteinase domain-containing 
protein 10 
AICD amyloid precursor protein intracellular domain 
ANOVA analysis of variance 
ApoE4 Apolipoprotein E4 
APP amyloid precurser protein 
BACE1 Beta site amyloid precursor protein cleaving enzyme 1 
CHL1 close homolog of L1 
CNS central nervous system 
3D three-dimensional 
et al. and others 
GFP green fluorescent protein 
h hour 
Hz Hertz 
i.p. intraperitoneal 
kg kilogramm 
LSM laser scanning microscope 
LTP long-term potentiation 
M molar 
MAP mitogen-activated protein 
mg milligram 
min minute 
mL milliliter 
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MRI magnetic resonance imaging 
NADH nicotinamide adenine dinucleotide 
NMDA N-Methyl-D-Aspartat 
2P two-photon 
PBS phosphate buffered saline 
PFA paraformaldehyde 
ROI region of interest 
s second 
SEM standard error of the mean 
Sez-6 seizure-related gene 6 
Thy1 thymocyte antigen 1; CD90 
TWA two-way ANOVA 
VGLUT1 vesicular glutamate transporter 1 
W watt 
WT wild type 
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